

NICOTINE AND THE SMOKING HABIT

D M Wadburn, Ph.D
Professor of Psychology
Department of Psychology
University of Reading
READING
RG6 2AL

May 1982

1002973414

CONTENTS

	<u>Page No.</u>
I INTRODUCTION	1
II NICOTINE PHARMACOKINETICS	3
A. <u>Absorption</u>	3
B. <u>Distribution</u>	6
C. <u>Metabolism and Excretion</u>	8
D. <u>Conclusion</u>	9
III NICOTINE CONTROL	10
A. <u>Preferred Cigarette Brands</u>	10
B. <u>Inhalation</u>	12
C. <u>Smoking Pattern</u>	12
D. <u>Nicotine Titration</u>	13
IV NICOTINE PHARMACODYNAMICS	30
A. <u>Neurochemical Action of Nicotine</u>	30
B. <u>Neurophysiological Action of Nicotine</u>	34
C. <u>Nicotine and Human Psychophysiology</u>	46
D. <u>Psychopharmacology of Nicotine</u>	51

1002973415

	<u>Page No.</u>
V NICOTINE USE IN PERSPECTIVE	79
VI CONCLUDING COMMENTS	88
REFERENCES	93-112

1002973416

I. INTRODUCTION

Smoking has been indicted by health authorities around the world as a practice which impairs health and shortens life. According to epidemiologists, smoking causes ill health and premature death through coronary heart disease, lung cancer, chronic bronchitis, emphysema and cancers of the upper respiratory tract and even if it does not always cause death or disablement, there is hypermorbidity for these diseases among smokers. Joseph Califano, former Secretary of the US Department of Health, Education and Welfare described smoking as "Preventable Public Health Enemy Number One" which has been convicted, "beyond reasonable doubt, of crimes against the public health" (Califano, 1980).

In this climate of political and medical opinion, it is not surprising that researchers are reluctant to state publicly that smoking can be beneficial in any way, and yet common sense argues that it must be. Smokers are exposed to considerable publicity about the health risks and so every smoker must have made some judgement about the additional risk to health of continuing to smoke. Since cigarettes continue to be purchased, we can only conclude that smokers consider that the risks are outweighed by smoking's benefits.

This belief of smokers about the beneficial effects of smoking is substantiated by this selective but balanced review of the literature on nicotine and the smoking habit. It shows that most smokers absorb nicotine into their bloodstream during the act of cigarette smoking. The nicotine acts on the peripheral nervous system, releasing hormones which reduce fatigue and on the central nervous system to provide more efficient processing of information. This efficiency of function, after nicotine intake, enables people (smokers and non-smokers) to perform better in work situations. In addition, nicotine has a sedative action reducing anxiety and anger. Smokers titrate their nicotine intake according to their view of the situation so that they obtain the appropriate dose of nicotine for stimulation or sedation. In this way, nicotine helps them cope with situational demands, and improves the quality of their lives.

1002973417

The pharmacokinetic properties of nicotine make smoking doses remarkably safe for normal healthy adults in comparison with other stimulant and sedative substances. Consequently there is a high benefit-risk ratio for nicotine versus other comparable agents. In my view, the unique pharmacological properties of nicotine make it an ideal substance for self-medication by inhalation if the smoke can be made less dangerous. It follows that the less hazardous cigarette will not be a product with low tar, low carbon monoxide and low nicotine but one with the reduction of some smoke constituents but sufficient nicotine (and commensurate taste) to satisfy the smoker, and so prevent more intensive smoking. This type of product would provide the benefits of smoking with minimum risk.

The idea is not new; on the contrary, it was proposed almost 10 years ago (Russell, Wilson, Patel, Cole and Feyerabend, 1973). However, at that time, neither technology nor prevalent thinking was ready for such innovation. Tar and nicotine league tables had only just been introduced, and the limitations of low delivery cigarettes were not yet apparent. Indeed, it is uncertain that all factions would accept such counsel even now. Current opinion is to reduce tar and nicotine conjointly, but such 'across-the-board' reduction in smoke delivery ignores the smoker's needs.

Examination of the evidence (US Surgeon General, 1979 & 1981) suggests that any health problems that may be associated with smoking are more likely to be related to the vehicle by which nicotine is carried (viz, the tar) than to nicotine itself. A more sensible approach to the less hazardous cigarette is thus to provide the smoker with the level of nicotine required, whilst minimising the uptake of unwanted smoke components. The reduction of many other constituents could be tolerated by smokers as long as sufficient nicotine remains: the continuous removal of nicotine, however, may prove ill-advised.

1002973418

11. NICOTINE PHARMACOKINETICS

Tobacco leaves have a nicotine content between 0.2% and 5% of the dry weight. In a cigarette there is about 10 to 20 mg of nicotine and 14 to 20% is transferred into the mainstream smoke so a 35 ml puff on a 1.2 mg cigarette will give a mouth level of 150-250 μ g of nicotine (Armitage, 1973). Tobacco smoke has about 2000 other compounds in it as a complex mixture of gases, uncondensed compounds and liquid droplets as an aerosol. The pH of the mainstream smoke ranges between 5.5 and 6.2 for flue cured cigarettes and between 6.5 and 8.8 for cigar and pipe smoke. The level of acidity is crucial in determining the site of absorption and the amount of nicotine taken from the aerosol.

A. Absorption

The first requirement for a chemical to produce a biological response is absorption. Nicotine from tobacco smoke is absorbed from the mouth, nose, and lungs and digestive tract and the amount absorbed from most sites depends on the acidity of the total smoke.

1. Oral Absorption

Nicotine base is readily absorbed by the buccal membrane from the particulate phase of smoke but, as the amount of free base depends on pH, the amount of nicotine absorbed orally depends on pH. When the pH is 5.35, about 0.4 per cent of the nicotine is present as the free base, while at pH 8.5 (alkaline), 85 per cent of the nicotine is present as the free base. Beckett and Triggs (1967) found in humans that from 1.2 mg of nicotine base about 6% was taken up at pH 5.5 and 25% at pH 8.5. Animal studies with nicotine solutions have shown that a carotid nicotine level of 100 ng/ml can be achieved at pH 6 in the mouth but this increases to 500 ng/ml at pH 8 (Armitage and Turner, 1970). Unpublished research by Dr M A H Russell and Dr K Wesnes, showed that buccal absorption from alkaline tablets containing 1.5 mg nicotine gave venous levels of 6.0 ng/ml at pH 6 and 10.5 ng/ml at pH 9. From these data it would be expected that very little nicotine

1002973419

would be absorbed orally from cigarette smoke (pH 5.5 to 6.2), perhaps as little as 30% (Armitage, 1973), although much more is taken up from cigar smoke (pH 6.5 to 8.8). In a bioassay study to compare oral absorption of cigar and cigarette smoke, Armitage and Turner (1970) introduced equal numbers of puffs of cigar smoke at pH 8.5 and of cigarette smoke at pH 5.4 into the mouth of an anaesthetised cat. The cigar smoke produced an increase in blood pressure in the femoral artery but cigarette smoke did not. In the same study the oral uptake of radioactively labelled nicotine was compared at pH 7 and pH 8, there was much more taken up when the pH was 8. Thus oral absorption appears to be important for cigar and pipe smokers but much less significant for cigarette smokers. Consequently, a crucial part of the cigarette smoking habit is the further manipulation of smoke by inhaling and then expelling through the nose and mouth or even just expelling through the nose.

2. Nasal Absorption

In order to account for the habit of snuff taking, which is found in many cultures, and the popularity of snuff taking among smokers working in munitions factories, it has been suggested that nicotine is absorbed by the nasal mucosa (Proosdij, 1960). Evidence for this explanation has come from two studies. Temple (1976) found that snuff taking resulted in measurable levels of nicotine and its major metabolites in urine. More recently, Russell described the time course of plasma nicotine that resulted from snuff taking by an experienced snuff taker (Russell, Jarvis and Feyerabend, 1980). Uptake of nicotine from the nasal mucous membrane was extremely rapid and nicotine concentrations of over 20 ng/ml were found in blood samples from a forearm vein. Therefore, it would seem probable that nicotine is absorbed from the nose during smoke manipulation but the absorbed amount is probably small in comparison with the uptake that results from inhalation.

3. Inhalation

The major site of nicotine absorption for cigarette smoke (and so for the majority of smokers) is the lungs. During inhalation, the smoke

1002973420

aerosol passes down the bronchi and into the alveoli. Particles of cigarette smoke are an ideal size ($0.01 - 2 \mu\text{m}$) for penetration into the alveoli and absorption occurs through the thin alveolar membrane into the pulmonary capillaries. It is estimated that more than 90% - 95% of inhaled nicotine is absorbed (Armitage, Dollery, George, Houseman, Lewis and Turner, 1974; Armitage and Turner, 1980; Artho and Grob, 1964). When equivalent sized boli of cigar or cigarette smoke were puffed into a cat's lung, changes in femoral artery blood pressure suggested much more efficient uptake of nicotine from cigarette smoke than cigar smoke (Armitage, Hall and Morrison, 1968). Nicotine diffuses so rapidly across the alveolar membrane and the velocity of blood flow through the capillaries is so slow that equilibrium is probably reached between alveolar nicotine and capillary nicotine ensuring maximum uptake. On the basis of the previous estimates of 150 to 250 μg mouth level of nicotine from each puff, over 100 μg would be taken up during each inhalation from a medium delivery cigarette (Armitage, Houseman, Turner and Wilson, 1974) giving over 1.0 mg of nicotine per cigarette. Of course, the actual intake may not only depend on smoke generation (puffing pattern) and smoke manipulation (quantity inhaled and depth of inhalation) but also perhaps on smoke moisture, pH of mucus membrane, and the contact time with the alveoli.

The time course of nicotine in human plasma has been studied most extensively by Dr M A E Russell. Smokers puffed ten times on a cigarette and plasma samples were taken every five minutes from an indwelling needle in a forearm vein. There was a rapid increase in plasma nicotine with each puff with irregularities in the ascent profile from the puff by puff boluses of nicotine. Peak venous nicotine levels of 15.5 to 38.4 ng/ml were reached at the end of the cigarette and then corresponded to about one fifth or one sixth of the carotid artery levels. Nicotine decay is not smooth either, and Russell (1976) argues that the irregularities represent nicotine redistribution and recycling. The estimated overall half-life in humans is around 20 mins after finishing the cigarette and baseline levels of about 7 ng/ml are reached in 40 mins.

1002973421

4. Gastric Absorption

Gastric absorption only plays a small part in nicotine uptake from cigarette smoking in normal circumstances. Nicotine from the smoke aerosol will dissolve in the saliva where pH ranges of between 5.6 and 7.6 would give about 6 per cent to 20 per cent free nicotine base. Travell (1967) showed that nicotine was rapidly absorbed from a cat's stomach when the solution pH was between 7.8 and 8.6 but not when the solution was acidic, with a pH between 1.2 and 4.2. There is evidence of active nicotine excretion from the salivary glands. This nicotine passes into the stomach and Russell (1976) has suggested that this "recycled" nicotine could maintain the plasma levels of nicotine in smokers. However this seems unlikely; the normal gastric pH is acidic and so nicotine will be absorbed very little from the stomach although absorption from other regions of the digestive tract cannot be ruled out.

5. Summary

The amazing, complicated practice of puffing on burning tobacco leaves, inhaling the smoke and blowing it out through the nose and mouth has a simple explanation. This procedure enables the most efficient transfer of nicotine from the tobacco leaves to the smoker's bloodstream and more importantly the smoker can control the level of nicotine intake (see Section III).

B. Distribution

After absorption into the pulmonary capillaries, nicotine does not bind to plasma protein and so all the nicotine is available for biological activity. The nicotine-loaded blood leaves the lungs via the pulmonary veins and passes through the left atrium of the heart into the left ventricles. From there the nicotine is pumped out into the aorta from which the large arteries branch off. The significant branch, from the point of view of the smoking habit, is the carotid artery which leads directly to the brain, so that some absorbed nicotine passes directly unmetabolised from lung to brain within 10 secs. About a fifth of the blood from the heart ascends in the carotid artery so that a fifth of the absorbed nicotine passes to the brain (Oldendorf, 1977) ie a dose of around 250 μ g from a medium delivery cigarette on the basis of the previous assumptions.

1002973422

1. Brain

In order to act on the brain, a substance must penetrate the blood-brain barrier (mainly the membrane lipid of the brain capillary walls) to the brain extracellular fluid. Nicotine is soluble in lipid (partition coefficient of 0.4) which suggests that it will freely pass through this barrier. Studies in the rat have compared the percentage of nicotine remaining in the brain 15 seconds after a rapid intracarotid injection with tritiated water as a standard. Ninety per cent of the tritiated water is taken up by the brain on the first pass through the brain, and uptake of nicotine is 13% that of tritiated water. (Oldendorf, Hyman, Brown and Oldendorf, 1972). Thus virtually all the nicotine that is delivered to the brain leaves the blood since the volume of brain tissue to which it can be distributed is so much larger than the capillary plasma volume. As a result, the amount of nicotine entering the brain is proportional to the cardiac output to the brain i.e. about 250 µg nicotine per cigarette. As a consequence of this efficient uptake of nicotine, doses affecting the brain can be obtained with relatively low blood levels which minimises the risk of toxicity to other organs in the body.

Whole body autoradiograms of mice given intravenous doses of ¹⁴C-nicotine reveal a high accumulation of nicotine in the grey matter (unmyelinated tissue) with much smaller quantities in the white matter. This distribution occurs because nicotine's partition coefficient of 0.4 allows good penetration of the blood-brain barrier but does not result in depot fat storage. Microautoradiograms after ¹⁴C-nicotine and ³H-nicotine show radioactivity in cortical cells, high levels in molecular and pyramidal cells of the hippocampus, the molecular layer of the cerebellum, the nuclei of the hypothalamus and the brain stem (Schmiederlów, Hanson, Applegren and Hoffman, 1967). This pattern of nicotine distribution throughout the brain allows wide scope for pharmacodynamic interaction.

1002973423

The time course of nicotine distribution in mouse brain shows that the maximum concentration is reached within one minute of an intravenous injection. The level then decreases rapidly to about 50 per cent in five minutes and one per cent after an hour (Stalhandske, 1970). Similarly Schmitterl w found a rapid nicotine decrease from 3.93 μg (per gram of brain tissue) at five minutes to 0.71 μg at 20 minutes and 0.10 μg at one hour (Schmitterl w, Hanson and Andersson, 1967). As these workers and others found, the brain does not metabolize nicotine but the drug washes out quickly from the brain and so gives a short duration of action. Thus nicotine is a drug which is rapidly absorbed into the brain, widely distributed and then quickly removed; the ideal specifications for a substance that is required for a short duration of action.

2. Rest of the Body

The nicotine that is eliminated from the brain is redistributed around the rest of the body and joins the nicotine introduced via the other arteries from the aorta. As the partition coefficient is less than one very little storage in solution in fatty tissues results. Instead, whole body autoradiograms (Schmitterl w et al 1967) show a pattern of distribution after intravenous injection that corresponds to the blood supply, with the highest levels of radioactivity in the liver (4% of the injected dose), about the same levels in the kidneys as in the brain (2% of the injected dose) and less in the stomach.

In contrast to the brain, nicotine is metabolised in the liver and kidneys (see next section) and nicotine levels in the liver fall from 8.12 μg (per gram of tissue) at five minutes to 0.76 μg at 20 minutes ie about 90% is metabolised in 15 minutes. At 20 minutes the radioactivity in the liver and kidneys is mainly due to cotinine and other metabolites of nicotine (Schmitterl w et al 1967).

C. Metabolism and Excretion

Metabolism and excretion have been discussed at length in numerous publications. However there are two aspects of major importance to the smoking habit. First, it is clear from the time course that nicotine

1002973424

is metabolised very efficiently by the liver, this limits nicotine's duration of action in the body. Second, the metabolites appear to be virtually inactive. Metabolic transformation is carried out by the enzyme systems of the liver microsomes and it seems that microsomal oxidation systems are protected by a lipid barrier (Brodie, Maickel and Jondorf, 1958) which nicotine is fat-soluble enough to penetrate. The major metabolic route is probably hydroxylation (insertion of a carbonyl group in the pyrrolidine ring) to form cotinine. In addition, other metabolites, including nicotine 1-N-oxide and normicotine, are formed and excreted. The importance of this metabolic outcome is that no compounds of demonstrated pharmacological action are produced and the pharmacodynamic effects are determined almost completely by the action of nicotine alone.

D. Conclusion

Studies of nicotine pharmacokinetics have revealed it to be a substance which is absorbed very efficiently from the lungs, readily enters and is quickly eliminated from the brain, and is rapidly metabolised to relatively inactive metabolites. This pharmacokinetic pattern allows a brief duration of action and the possibility of central nervous action with minimum side effects from actions on the rest of the body. The realization of this possibility depends on the ability of the smoker to control his exposure to nicotine ie titrate for nicotine.

1002973425

III. NICOTINE CONTROL

The first argument for the relevance of nicotine to the smoking habit comes from evidence that people smoke to obtain nicotine, and many of them appear to regulate nicotine intake to obtain specific levels of nicotine in their bloodstream. The implication of titration is that smokers have need for nicotine and possess a mechanism in the body which is sensitive to nicotine so enabling them to titrate the dose. Evidence for nicotine need and titration has come from surveys of cigarette preference, studies of inhalation, studies of smoking patterns throughout the day, the titration of individual cigarettes, nicotine preloading studies and a nicotine antagonist experiment.

A. Preferred Cigarette Brands

In 1957 the Readers' Digest magazine published a list of the deliveries of nicotine and total particulate matter from cigarette brands in the United States. At that time only one per cent of the cigarettes were filter type and the average cigarette delivered 2.5 mg of nicotine and around 36 mg of particulate matter. After the adverse publicity in the United States from the Surgeon General's report in 1964, and the reports in 1962 and 1971 of the Royal College of Physicians in Britain, the average levels of nicotine, determined by smoking machine analyses, were 1.3 mg. After 1966, American cigarette manufacturers cited tar and nicotine levels in their advertisements and competition began, between the manufacturers, to introduce lower delivery cigarettes onto the market. In 1977 just under half of the United States cigarette industry's budget for advertising and promotion was used to encourage the purchase of these products (US Public Health Service, 1979), and a similar pattern has occurred in the United Kingdom.

It might have been expected that the combination of government publicity and company promotion would have produced an even more remarkable switch in brands to lower nicotine and tar yields in the following ten years, and the sales-weighted average nicotine per cigarette would have decreased at least a further 1.0 mg to 0.3 mg. In fact, cigarettes with a nicotine

1002973426

content of 0.3 mg and correspondingly low levels of particulate matter are not popular, and the sales-weighted average level of nicotine in UK cigarettes has been 1.3 - 1.4 mg per cigarette for the past 8 years, and in the United States it is only approaching 1.1 mg. In Germany there is a similar pattern and the sales-weighted average of nicotine did drop to 0.6 mg but is now around 0.8 mg. The Germany figure may be lower because the Ph of alkaline so increasing absorption (see Section II A). Nicotine-free cigarettes have been a total disaster, even though many people have tried them. Clearly, smokers not only prefer nicotine-containing cigarettes, but most smokers select brands which give a machine smoking delivery of above 1.0 mg of nicotine.

It could be argued that these observations on cigarette preferences do not provide convincing evidence for the importance of nicotine because nicotine usually co-varies with particulate matter in cigarette brands as a consequence of the manufacturing techniques. However, one controlled study has tested cigarettes with independently varied nicotine and tar levels. (Goldfarb, Jarvik and Glick, 1970). Smokers were allowed to smoke as many as they wished of these cigarettes with varying amounts of nicotine and the number of cigarettes that they smoked correlated with nicotine content but not tar content. Ratings of satisfaction and the perceived strength of the cigarette were similarly correlated with nicotine content rather than tar content. Nevertheless, it is interesting that non-nicotine cigarettes were smoked to some extent over the three weeks of the test when there were no other alternatives.

Although low and zero nicotine cigarettes allow the smoker to go through the rituals of lighting, manipulating, and puffing the cigarette as well as inhaling the smoke, the lack of nicotine results in lower consumption. However, it would be fallacious to conclude that flavour from the particular phase of tobacco smoke plays no part in the acceptability of a cigarette. Nevertheless, the inference from these surveys and studies is that nicotine is an essential ingredient of the cigarette for the smoker and this conclusion becomes even clearer when a more complete measure of smoking behaviour, than number of cigarettes smoked, is used.

1002973427

B. Inhalation

As discussed in Section II, smoke inhalation results in very efficient absorption of nicotine; the large percentage of smokers who inhale provides evidence that the aim of smoking is to obtain nicotine. Epidemiological studies of smoke-related diseases have surveyed self reported inhalation behaviour (Doll and Hill, 1964; Hammond, 1966). Doll and Hill's study showed that 80 - 90 per cent of cigarette smokers reporting inhaling, and Hammond found that 96.4 per cent of smokers, aged between 40 and 49, said that they inhaled to some extent and 85.6 per cent thought that they were moderate to deep inhalers. Todd (1968; 1971) reported similar data with 9 per cent and 8 per cent of smokers believing that they did not inhale at all and 77 per cent saying that they inhaled "a lot" or "a fair amount". The problem with self reported inhalation data is that it may be inaccurate because smokers underestimate the extent to which they inhale (Castleden and Cole, 1973). Therefore the percentage of inhalers is probably higher than these surveys suggest, strengthening the argument that smokers use cigarettes to obtain nicotine.

C. Smoking Pattern

The hypothesis that smokers attempt to maintain minimum (or above) levels of nicotine is supported by studies of plasma levels of nicotine throughout the day (Russell, Wilson, Patel, Cole and Feyerabend, 1973; Russell, Wilson, Patel, Feyerabend and Cole, 1975). The half-life of nicotine in plasma (see Section II) is about 20 to 30 minutes and habitual smokers consumed 15 to 30 cigarettes per day, ie a cigarette every 30 to 50 minutes (excluding meals and sleep). Russell's studies demonstrated that the mid-morning levels of plasma nicotine were remarkably consistent within subjects across days (small standard error), although the levels for individuals ranged from 5.6 to 83.3 ng/ml. A determination five hours later in the afternoon showed that these levels were either virtually the same or higher which again supports the hypothesis that smokers use cigarettes to obtain nicotine.

1002973428

D. Nicotine Titration

In this part I will consider the direct evidence for smokers controlling their nicotine intake either by smoking less intensely with higher delivery cigarettes or smoking more intensely with lower delivery brands. For convenience this section will be sub-divided into cigarette consumption, smoke generation and smoke manipulation, and within each sub-section, the methods of study.

1. Cigarette Consumption

The number smoked is the most obvious way for smokers to control their nicotine intake and it is the easiest to study. However, as we shall see, it is not without its problems. For instance, the number of cigarettes in a pack has a strong influence on consumption. The first studies examined the effects of changing the cigarette brand on consumption.

a. Cigarette Switching

The findings of Russell et al (1973; 1975), which strongly hinted that smokers control their nicotine intake were explored further by switching the subjects from their usual brand (1.5 mg average) to both high (3.2 mg) and low (0.3 mg) nicotine cigarettes on different days. The number smoked during the five hours in the middle of the day was recorded. When switched to the high nicotine cigarette, consumption of the group dropped by 37 per cent, from 10.8 ± 3.5 to 6.7 ± 1.6 , and increased, by 17 per cent, from 10.7 ± 3.5 to 12.5 ± 3.2 , when they changed from their usual brand to a low nicotine cigarette (average = mean \pm standard deviation). The decrease with the high nicotine delivery cigarette was significant but the increase with the low nicotine delivery cigarette was not. However, in terms of nicotine delivery of the latter product, subjects would have needed to smoke five times as many to compensate (an increase from 10.7 to 53.5) if they did not change other aspects of their smoking behaviour in any way.

1002973429

A large scale interview study which looked at the number smoked has given similar findings for switching to lower yield brands. Waingrow and Horn (1968) interviewed a group of 1466 cigarette smokers in 1964 and again in 1966. They found no evidence that smokers, who switched to lower delivery cigarettes, increased their consumption. However, it was again assumed that the smokers did not change their smoking behaviour to obtain more nicotine. Russell (1976) has also pointed out that there may have been self-selection in the sense that only smokers with a low requirement for nicotine switched brands and so could accept the reduced delivery without feeling deprived.

In a shorter term laboratory study, Frith (1971) gave smokers cigarettes with deliveries of 1.02 mg, 1.37 mg and 2.11 mg of nicotine to smoke on single days. The number of cigarettes that were smoked was recorded throughout the day from 9.00 am to 5.00 pm, and the smokers also rated their desire to smoke before and after each one. An inverse relation was found between the number of cigarettes smoked and the nicotine level. Subjects also said that they found the high delivery cigarette more satisfying than the low delivery. Unfortunately, the tar level of the lowest cigarette was half that of the highest (14.6 against 30.8) and so the subjects could easily detect the differences between the products. In a better two hour experiment, smokers were given specially prepared cigarettes which were either of low nicotine delivery (0.2 mg) or high nicotine delivery (2.0 mg) (Jarvik, Popek, Schneider, Baer-Weiss and Gritz, 1978). The tar levels of the cigarettes were identical so that the taste difference was small. Subjects smoked more of the lower delivery than the higher delivery cigarette which gives persuasive support for nicotine regulation.

Better controlled studies have looked at smoking in real life situations. In the first, smokers were given a medium delivery cigarette for the first week, a low to medium cigarette in the second week, and a low cigarette in the third week (Turner, Sillet and Ball, 1974). The subjects compensated by smoking significantly more cigarettes when they switched from the medium to the low-medium cigarettes, but there was little change after the second switch from low-medium to the low delivery product. A longer study (Freedman and Fletcher, 1976)

1002973430

examined the changes in consumption over a 20 month period when smokers were switched from a conventional medium (1.39 mg) nicotine cigarette to a lower medium (1.01 mg) cigarette containing 30 per cent tobacco substitute. The average number of cigarettes smoked remained constant for the first 15 months, but increased slightly in the last 5 months. Although consistent with nicotine regulation, this small but significant increase was surprising in view of the similarity of the nicotine yields of the two cigarettes.

The problems of cigarette consumption experiments were highlighted by long term studies by Adams (1976; 1978) of smokers from the Imperial Tobacco Company Research Division and Head Office which will also be referred to later. Two sets of subjects smoked their own brand for a week, then medium nicotine (1.4 mg) cigarettes for five weeks and then a low-medium nicotine (0.8 mg) cigarettes for four weeks. Two control groups smoked their own brand for a week and then either the low cigarette or low-medium cigarette for the remaining nine weeks. The Research Division subjects increased their weekly consumption markedly when switched to the low nicotine product while the Head Office subjects increased their number only slightly. Adams believes that members of the Head Office smoking panel were less familiar with the experimenters and were inhibited in their demands for more free cigarettes. An equivalent psychological barrier may operate in real life where smokers may choose a lower delivery brand but are reluctant to purchase more cigarettes than they usually do.

A methodologically sophisticated long term study was performed by Finnegan, Larson and Baag (1945) using tobacco leaf with naturally low nicotine content made into a low nicotine (0.34 mg) cigarette or the same leaves sprayed with nicotine and made up into a high nicotine (1.96 mg) cigarette. Thus the pressure drop of the cigarettes and the tar level would be the same and, although the nicotine would give a slightly different taste, it was possible to test the effects on consumption without the subjects being certain about the difference. Subjects were given 400 of the high nicotine product followed by a month on the low nicotine brand and then switched back to 400 of the high nicotine cigarette. The authors claimed that there was no

1002973431

correlation between the number of cigarettes smoked and the nicotine level, a finding which argues against compensation. However, an interesting picture emerged when Russell (1976) examined the distribution of withdrawal symptoms in this study; subjects who did not increase their consumption on the low nicotine cigarette experienced lack of satisfaction, irritability and poorer concentration.

Instead of examining a mixed set of subjects, as in the last study, Schachter (1977) selected an "addicted" group and a "non-addicted" group. The addicted group members had smoked at least 20 cigarettes a day for many years, they smoked regularly throughout the day from morning to night, they inhaled the smoke, they were not trying to stop or cut down at the time of the study, and, if they had tried to abstain, then they had experienced abstinence symptoms. Half the subjects were given low nicotine (0.3 mg) cigarettes for the first week and half were given medium nicotine (1.3 mg) cigarettes for the first week, then they were switched to the other cigarette for the second week. Although the experiment was carried out double blind the cigarettes differed to some extent in tar content. As a group, the addicted smokers smoked 24 per cent more of the low nicotine cigarettes (42.93) than the high nicotine (34.57), while the light smokers used 16 per cent more of the low nicotine (10.19) compared with the high nicotine cigarette (8.81). Schachter reported that three addicted subjects, who only increased consumption by 14.3 per cent compared with 33.6 per cent for the rest, experienced severe abstinence symptoms. Thus the last two studies show that smokers who do not regulate their nicotine intake, suffer deprivation symptoms.

b. Ventilated Holder

Another method of varying smoke delivery to the smoker is to use a normal cigarette but smoked through a ventilated cigarette holder. Two holders producing nicotine dilutions of 23 per cent and 58 per cent were used to study titration (Sutton, Russell, Feyerabend and Sallojee, 1978). Smokers used each holder for a week and kept a diary of their cigarette consumption. Consumption remained constant

1002973432

throughout the study and no titration was seen on this measure. However, as we will see later, compensation was achieved by increasing the amount of smoke inhaled.

c. Partial Cigarettes

A third type of study has examined the number smoked when subjects were only allowed to smoke part of a cigarette for a week. Goldfarb and Jarvik (1972) gave smokers packs of cigarettes which were either cut in half or had a line drawn around them halfway down, and the number of smoked cigarettes was counted. In comparison with smoking their own brand in week 1 (25.5), smoking increased with the lined cigarette (27.2) and the cut cigarette (28.6), but during the fourth week on their own brand smoking was also higher (27.3). These group data give limited support for titration by increasing the number smoked because 12 subjects did increase by an average of five a day on the lined cigarettes and by an average of seven a day on the cut cigarettes. A more extensive study (Russell, Sutton, Feyerabend and Cole, 1978) included a full length medium nicotine (1.08 mg) cigarette, a threequarter length, low-medium nicotine (0.63 mg) cigarette and a half length, low medium nicotine (0.67 mg) cigarette. These cigarettes were smoked in the laboratory on three separate afternoons. The number smoked increased from 13.6 with the full length cigarette, 14.8 with the threequarter length and 17.6 with the half length. Thus there was a clear and significant increase in consumption, in contrast to the rather small changes found by Goldfarb and Jarvik.

d. Nicotine Preload

A fourth approach has been to preload the smokers with nicotine, either by injection or oral doses. The pioneer study of this type, and indeed the first study of titration, was done by Johnston (1942). He injected 20 mg of nicotine intravenously and reported that smokers found the sensation pleasant and did not want to smoke for some time afterwards. No details were given of number consumed. In a follow-up study (Lucchesi, Schuster and Emley, 1967), subjects were given intravenous infusions of nicotine and their cigarette consumption examined. Low

1002973433

doses of nicotine had no effect, but 4 mg per hour very significantly reduced consumption of a cigarette of unspecified delivery by 27 per cent (10 to 7.3). Although significant, this decrease in numbers is small in comparison with the amount of nicotine given, but it must be remembered that nicotine is rapidly metabolised by the liver (see Section II) so that the levels reaching the brain would be much smaller than those infused.

The same problem applies to studies using oral nicotine whether in tablet or chewing gum form so that it is scarcely surprising that a daily dose of five tablets of 1.0 mg of nicotine reduced the number of cigarettes used by only eight per cent although this was a significant decrease (Jarvik, Glick and Nakamura, 1970). Nicotine chewing gum has been prescribed as a stopping-smoking aid; and some success has been claimed. In an experimental study (Russell, Wilson, Feyerabend and Cole, 1976), subjects were given either alkaline gum with nicotine (a high pH increases buccal and gastric absorption; see Section II A.1), or a placebo, both highly spiced so that the subjects could not tell which was which. A plasma nicotine determination showed that nicotine was absorbed from the nicotine gum although blood levels were lower than with smoking. Subjects reduced their smoking on both gums but significantly more so while taking the nicotine gum (37 per cent) than after the non-nicotine gum (31 per cent). Clearly, in spite of a placebo effect, when the subjects thought that they were getting nicotine gum, there was some reduction of consumption.

e. Modified Excretion

A fifth type of study manipulated nicotine body levels by changing urine acidity. If the urine is alkaline then less than one per cent of the nicotine is excreted unchanged in the urine, if it is neutral then seven per cent is excreted and if the urine is acid then 35 per cent is excreted unchanged (Beckett and Triggs, 1967). Presumably an increase in urinary excretion should lower plasma levels of nicotine and so Schachter predicted that increasing acidity should increase smoking. In a test of this prediction (Schachter, Kozlowski and Silverstein, 1977) ascorbic acid (Vitamin C) or glutamic acid

1002973434

hydrochloride was given to smokers to acidify their urine and increase excretion. There were increases in consumption from 23.1 to 26.7 (15.6 per cent) and 28.1 (21.6 per cent) respectively. Once again there was some evidence for control of nicotine intake by changing consumption.

f. Nicotine Antagonists

A complementary study to those on nicotine loading is one using the secondary amine, mecamylamine, which crosses the blood brain barrier and blocks nicotinic synapses in the central nervous system (Stolerman, Goldfarb, Fink and Jarvik, 1973). Smokers were given this drug or pentolinium, a nicotinic blocker which does not enter the brain, and asked to record the number that they smoked of their usual cigarettes (range 1.0 - 1.5 nicotine). Mecamylamine, (7.5 mg, 12.5 mg, 17.5 mg and 22.5 mg) increased cigarette consumption by as much as 30 per cent, presumably smokers smoked more to overcome the partial nicotine blockade in the brain and so obtain the desired effects of nicotine. When the smokers had taken pentolinium there was no change in the number of cigarettes smoked which ruled out any influence of the peripheral effects of nicotine on consumption. This study shows clearly that smokers are using cigarettes to obtain plasma levels of nicotine sufficient to affect the brain.

g. Summary

These studies show that some subjects titrate nicotine by changing the number of cigarettes that they smoke. In studies where abstinence symptoms have been examined, some smokers, who do not compensate, suffer from the effects of nicotine deprivation. However, negative studies may be explained in terms of changes in either puffing or inhalation. Data, that show these factors play a part, come from an experiment by Gritz, Baer-Weiss and Jarvik (1976) in which subjects were given an equal number of full length cigarettes and half length cigarettes to smoke in a week. Urinary nicotine measures showed that subjects were able to obtain considerably more nicotine than expected

1002973435

from the half length cigarettes, and indeed almost as much as from the full cigarette. The authors concluded that "frequency of puff, size of puff or depth of inhalation must have altered on the shorter cigarette to maximise nicotine intake and achieve optimal titration". (P.554).

2. Smoke Generation

In the last section, the conclusions on cigarette consumption were related to the nicotine content of the cigarettes. These nicotine levels were calculated on the basis of nicotine deliveries that were obtained from standard smoking machines. The machine smoking determinations enable comparisons of cigarettes, but the smoking machine only produces an approximation of human smoking. The underlying principle of the machine determination of smoke deliveries is that standard analytical procedures are such that the yield is representative of the smoke a cigarette delivers to the smoker if the same smoking parameters are applied. In an innovative series of studies, Creighton and Lewis (1978 a and b) recorded the pattern of smoking in terms of number of puffs, puff interval, puff volume and puff shape. They found that there were marked interindividual differences in smoking pattern and clear, but smaller, intraindividual variations. Therefore it was inevitable that an individual's pattern of generation rarely matched the smoking machine's standard parameters. The consequences of variations in smoking pattern for nicotine deliveries were smaller than those for total particulate matter and carbon monoxide. Nicotine increased markedly with the number of puffs, but there were only small changes for puff interval and puff volume, while puff shape had no effect on nicotine delivery.

The practical consequence of these variations in smoking pattern, in terms of nicotine deliveries, was examined in a complementary study with the puff duplicator (Creighton and Lewis, 1978 a). The divergence of the standard smoking machine yields from the actual values delivered can be seen by comparing the average amount of nicotine that was deposited on the Cambridge filter pad after duplicating the smoking patterns for a medium delivery cigarette having a yield of 1.4 mg of nicotine when analysed on a machine smoking to standard parameters. This was 2.25 mg

1002973436

of nicotine for males and 2.0 mg of nicotine for females. The coefficient of variation for nicotine deliveries between different subjects who smoked the same brand ranged from 24 per cent to 38 per cent with a mean of around 30 per cent. Clearly the machine estimated delivery is a limited index of the nicotine dose entering a smokers mouth, and so other estimates of nicotine delivered to the mouth should be used.

Some of the previous studies of nicotine regulation recorded puff variables as well as numbers of cigarettes consumed. The experiment of Frith (1971) demonstrated that, as well as smoking more cigarettes, smokers took larger puff volumes for some cigarettes than others. Lucchesi et al (1967) found that intravenous nicotine reduced the number of puffs and the subjects discarded their cigarette earlier. A similar study by Kumar (Kumar, Cooke, Lader and Russell, 1977), however, found no changes in puff number, interpuff interval, puff duration or puff volume on a 1.3 mg cigarette after 10 rapid injections of nicotine; either 0.035 mg/kg or 0.07 mg/kg spaced at one minute intervals in order to simulate 10 puffs on a 0.85 mg or a 1.7 mg cigarette. A companion study, with controlled smoking of either a herbal cigarette, a 1.3 mg nicotine cigarette or two 1.3 mg nicotine cigarettes (ie 2.6 mg) did reduce the number of puffs taken from a cigarette in a dose dependent fashion. The major problem with comparing studies of intravenous and inhaled nicotine is that some of the intravenous nicotine is metabolised before reaching the brain and so the dose is lower than that going from lung to brain. This evidence suggests that smokers can control the nicotine intake to their mouth by changing their smoke generation. Direct studies of this behaviour have employed cigarette switching and partial cigarettes.

a. Cigarette Switching

Estimates of nicotine which is drawn into the smokers mouth have been made from analyses of the nicotine deposited in the cigarette filter and the filtration efficiency of the filter tip. One of the first studies on butt nicotine allowed smokers to smoke either a 1.0 mg or 2.1 mg nicotine cigarette while in a driving simulator (Ashton and Watson, 1970). Records were made of puff number and depth of inhalation while the butts were collected. Depth of inhalation was

1002973437

unchanged but puff number was large on the medium delivery cigarette and butt nicotine data showed that about the same amount of nicotine was delivered to the mouth from both cigarettes (1.31 mg from the 1.0 mg nicotine cigarette, a ratio of 1.31, and 1.55 from the 2.1 mg nicotine cigarette, a ratio of 0.74). This study gave clear evidence of titration, by smoking the lower delivery cigarette more intensely and puffing the higher delivery product less intensely. In our own studies (Warburton and Wesnes, 1978) we found similar changes during a vigilance test. Smokers smoked both a low nicotine (0.3 mg) delivery cigarette and a low-medium nicotine (0.7 mg) cigarette more intensely and an estimated 0.68 mg and 1.3 mg of nicotine entered the mouth (ratios of 2.28 and 1.85). When they smoked a 1.64 mg nicotine cigarette, slightly less intensely, they obtained an estimated 1.55 mg of nicotine in the mouth (a puffing intensity ratio of 0.94).

In the longer term study by Turner et al (1974) there were differences in the number of cigarettes smoked between a medium nicotine and a low-medium nicotine product but not between the low-medium and a low brand. There was little difference between the medium and low-medium nicotine cigarettes (puffing intensity ratios of 0.62 and 0.77) but subjects puffed the low delivery cigarette more intensely (a puffing intensity ratio of 1.23). Clearly, the same subjects titrated by changing either the number smoked or the smoke generation in order to obtain their desired nicotine level. In the even longer study by Freedman and Fletcher (1976), in which there were only small changes in the numbers smoked when subjects switched from a 1.39 mg nicotine cigarette to a 1.01 mg product, butt nicotine levels also showed more intense smoking of the lower brand in comparison with the higher delivery cigarette. Puffing intensity ratios of 1.06 and 0.81 were found according to a reanalysis of the data by Rawbone (1976). In another long cross-over study, smokers were studied for four weeks, one week on their usual brand, two weeks on a low delivery cigarette and the final week back on their own cigarette (Forbes, Robinson, Hanley and Colburn, 1976). From butt analysis there was poor evidence of compensation although the subjects were allowed to select their own low delivery product which makes it difficult to draw firm conclusions.

1002973438

As part of their studies using the puff recorder and puff duplicator, Creighton and Lewis (1978 a) studied cigarette switching. Smokers smoked a medium nicotine (1.4 mg) cigarette for one month, a high nicotine (1.8 mg) cigarette for the second month and the medium cigarette again for the third month. The estimated amount of nicotine that was delivered to the mouth of the smoker was assessed from ten laboratory sessions within each month. It was found that the level of nicotine delivered to the mouth stayed constant because subjects reduced their puffing intensity when they switched from medium delivery to high delivery cigarettes and increased their smoking intensity for the opposite switch from high cigarettes back to medium delivery products. However, subjects did not achieve mouth deliveries of 2.0 mg; men obtained 1.7 mg but women only achieved 1.0 mg in spite of their increased smoking intensity. Creighton and Lewis (1978 a) believe that this effect was due to cigarette construction ie, ventilation and longer apparent tip which inhibited smoking to the usual butt length. The clear conclusion was that smokers changed their smoking intensity in the direction of equalising nicotine deliveries. There was no evidence, in this study, that smokers modified the number smoked each day.

In another series of recordings of smoke generation, Adams (1976; 1978) measured puff number, puff volume and puff duration, as well as butt nicotine. He also found that smokers behaved differently on a low-medium nicotine (0.8 mg) cigarette in comparison with a medium delivery (1.4 mg) cigarette; they puffed harder on the lower delivery product and left a shorter butt. Butt nicotine analysis confirmed that more intense smoking resulted in proportionally more nicotine being taken into the mouths of smokers from the low nicotine than from the high nicotine cigarettes. A similar switching experiment (Rawbone, Murphy, Tate and Kane, 1978) studied smokers before and after they switched from their own medium delivery brand (average 1.22 mg of nicotine) to an undefined "low" delivery product. They found that subjects smoked harder on the lower delivery cigarette in comparison with their medium cigarette and compensated quite well (0.83 mg for low-medium against 0.96 mg for the medium delivery brands); as a result of increased puff volume. No increase in consumption was seen.

1002973439

b. Partial Cigarette

In a partial cigarette study, Ashton and her colleagues (Ashton, Stepney and Thompson, 1978) tested subjects with two versions of their usual cigarettes throughout the study; a full length and a two-thirds length, which was calculated for each individual in the following manner. Subjects brought in the butts of their cigarettes, for a 24 hour period, and these were measured. The amount of the cigarette normally smoked was calculated and then a mark was made on the paper at two thirds of this length to indicate the amount of tobacco that they could smoke. The subjects were issued with the same number of marked cigarettes as they had smoked on the previous day and asked not to supplement them. In this way each smoker was deprived to the same degree but not by the same absolute amount. Comparative studies in the laboratory showed that subjects, given the two-thirds cigarettes, increased their puff duration and decreased their puff interval showing more intensive smoking of the reduced cigarette. However, the butt nicotine estimates showed that subjects did not compensate for the reduction sufficiently to obtain their usual amount of nicotine, as smokers had done in the study of Gritz et al (1976). The reason for this difference lies in the part of the cigarette that was smoked in the two studies. It is thought that about 61 per cent of nicotine in the smoke aerosol comes from the half of the cigarette nearer the filter, and only 39 per cent from the other half (Gritz et al, 1976) and so the subjects were not able to compensate sufficiently in the Ashton et al study.

c. Summary

These studies have examined the smoking intensity of low and high delivery brands by estimating the nicotine delivered to the mouth of the smokers from either the amount of nicotine that was deposited in the cigarette butt or puff duplication. The conservative conclusion from this body of data is that there are many different ways of smoking (machine deliveries being merely yields obtained from smoking to a standard set of parameters), and that subjects tend to smoke low delivery cigarettes more intensively and smoke high delivery brands

1002973440

less intensively, even allowing for uncertainties of the filter tip analysis method (Creighton and Lewis, 1978 a).

It should be noted that although the filter tip analysis and puff duplication give an estimate of the amount of nicotine that is delivered to the mouth of the smoker, the value does not represent the effective dose because nicotine is not readily absorbed by the mouth from acidic smoke (see Section II A.1). Cigarette smoke must be inhaled for maximum absorption of nicotine. Of course over 90 per cent of smokers say that they usually inhale to some extent and 77 per cent say that they usually inhale "a lot" or "a fair amount" (Todd, 1972 TRC) so it is likely that a high percentage of the nicotine actually retained in the mouth is made available for absorption by the lungs, but accurate measures of the nicotine titration can only come from first estimating the amount of unwanted nicotine rejected from the mouth before inhalation (the "waste smoke") and then measuring inhalation itself.

3. Smoke Manipulation

Smoke manipulation particularly inhalation was apparently the most surprising aspect of the smoking habit for the Spaniards who first saw the American Indians smoking, but it is this manipulation which enables nicotine absorption. One index of manipulation is the amount of carbon monoxide exhaled after a cigarette. Carbon monoxide is absorbed into the bloodstream from the lungs and not in the mouth, so that increased carboxyhaemoglobin occurs only after inhalation. When the residual smoke has been expelled from the lungs, after a cigarette, carbon monoxide exchange from the blood to the lungs will occur so that the level of exhaled end-tidal carbon monoxide provides an index of uptake at the lungs and so enables comparisons of smoke manipulation.

a. Cigarette Switching

In a study referred to twice before, switching from smoking medium nicotine (1.4 mg) cigarettes to either high nicotine (3.2 mg) or low nicotine (0.3 mg) cigarettes was compared over a five hour work period by measuring exhaled carbon monoxide (Russell et al, 1973).

1002973441

The problem of interpreting the results was the difference in carbon monoxide yields of the two cigarettes and the fact that the subjects slightly increased consumption of the low delivery and decreased the number of higher delivery cigarettes smoked. Exhaled carbon monoxide decreased for both switches and Russell has argued post hoc that the decrease with the high cigarettes represented less inhalation while the decrease with the low cigarettes was attributable to the lower carbon monoxide yield of that product. Plasma nicotine measures showed clear titration in half of the subjects when switched to the high nicotine cigarette while there was some evidence of titration for the group as a whole when switched to the low nicotine cigarette. When Ashton and Telford (1973) used unspecified high nicotine cigarettes and low nicotine cigarettes but with the same carbon monoxide delivery, the levels of exhaled carbon monoxide were inversely proportional to the nicotine deliveries of the cigarettes giving evidence of titration smoke manipulation.

Strong support for this conclusion was obtained from subjects who switched from a high nicotine (1.7 mg) cigarette with 17.2 mg of carbon monoxide to a low-medium nicotine (0.7 mg) cigarette with only 11.4 mg of carbon monoxide for five weeks (Guillerm and Radziszewski, 1974). Consumption increased slightly by three a day but carbon monoxide levels increased from 5.78 per cent to 7.43 per cent even though the machine estimated delivery of carbon monoxide from the low-medium nicotine cigarette was lower. In contrast, the shorter study of Turner et al (1974) found only slight evidence for compensation by smoke manipulation on the lower delivery brands.

More convincing evidence comes from an eleven week crossover study (Ashton, Stepney and Thompson, 1978) in which smokers switched from their usual medium (1.4 mg) nicotine brand to either high (1.84 mg) nicotine cigarettes ie an increase of 31 per cent in delivery or low-medium (0.6 mg) cigarettes ie a decrease of 57 per cent in delivery. The exhaled carbon monoxide levels showed an increase of only 10 per cent on the high nicotine cigarette, and were only 15 per cent lower on the low-medium cigarette. The plasma nicotine levels showed a similar pattern indicating that considerable post

1002973442

puffing titration had occurred. Urinary nicotine excretion on the high nicotine cigarette gave no support for titration when the machine delivery of 31 per cent higher than the usual brand was matched by urinary nicotine levels 30 per cent higher with the high nicotine cigarette than with the usual brand. However with the low nicotine cigarette, at 43 per cent of the usual cigarette the 24 hour excretion was 94 per cent. Altogether this study gives strong support for nicotine titration by smoke manipulation.

b. Partial Cigarettes

The experiment with half and three-quarter length cigarettes of Russell et al (1978) also included determinations of exhaled carbon monoxide and plasma nicotine. Although smokers used a greater number of the partial cigarettes, there was no evidence that they inhaled more carbon monoxide than would have been expected from the size of the cigarettes and the plasma nicotine was at the expected level as well, suggesting no titration. We will return to this contradictory result in the next sub-section.

c. Ventilated Holder

The results of the study on the ventilated holder (Sutton et al, 1978) which gave no support for titration in terms of the number smoked did provide some evidence for titration by smoke manipulation. A comparison of the observed 33 per cent reduction of carbon monoxide by the more ventilated holder at two days and seven days with the expected reduction of 52 per cent showed partial but significant compensation which was maintained throughout the test week. There seemed to be no compensation with the less ventilated holder which reduced carbon monoxide by 15 per cent. The outcome, in terms of plasma nicotine, was a reduction of only 40 per cent instead of the expected 58 per cent which confirms the effectiveness of smoke manipulation as a titration mechanism. This clear finding contrasted with the study of Russell et al (1978; Russell, 1980) in which partial cigarettes were smoked. Although smokers consumed more cigarettes in this study, their expired carbon monoxide and plasma nicotine levels were the same as those predicted if no titration had occurred. This study implies that smoke concentration is the cue for smoke manipulation because total

1002973443

smoke inhaled increased for smoke diluted by ventilation but not when the smoke concentration was the same as in the partial cigarettes (Russell, 1980).

d. Nicotine Preloading

As part of a series of studies on titration we administered an oral 1.0 mg dose of nicotine to smokers prior to smoking a low-medium nicotine (0.6 mg) cigarette (Wesnes, Pitkethley and Warburton, in preparation). The subjects were not told the true nature of the study and thought they were participating in a study of smoking and the effect of absorption of pure nicotine on hand tremor. Puffing behaviour, butt nicotine and exhaled carbon monoxide were measured. No differences were seen in puff duration and puff interval or the butt nicotine levels for the nicotine and placebo conditions. However, there was a significant reduction of exhaled carbon monoxide after the subjects had received a nicotine tablet indicating reduced smoke inhalation. Clearly the smokers were titrating their nicotine dose by smoke manipulation according to some internal mechanism sensitive to plasma nicotine levels.

e. Summary

Nicotine intake can be controlled by the amount of smoke inhaled as well as by cigarette consumption and by smoke generation. The amount of smoke inhaled depends on a combination of the quantity of waste smoke (the surplus expelled before inhalation) and the degree of inhalation. Rawbone et al (1978) compared exhaled carbon monoxide levels with smoke generation measures and found no correlation. Some smokers puffed relatively little but perhaps wasted little and inhaled the remaining smoke deeply, others puffed hard but perhaps wasted more and inhaled little. Thus, mechanisms are not necessarily interdependent. As far as nicotine absorption is concerned, inhalation is the final control on intake.

1002973444

4. Conclusions

The experiments in this section were designed to investigate to what extent nicotine intake was controlled and the changes in smoking behaviour that enabled control. Taken together the studies show that nicotine intake is titrated to obtain more nicotine from lower delivery cigarettes and less nicotine from higher delivery brands. The methods of titration are number of units smoked, the length of cigarette smoked, the intensity of smoke generation, and the amount of smoke manipulation (waste smoke and inhalation). Unfortunately, most studies have only studied one of these titration mechanisms and found that some subjects do titrate, some titrate partially and some may not titrate at all using that particular method. Indeed it may be possible to titrate completely with some low delivery brands and the plasma nicotine levels in the studies of Russell support this assertion.

Evidence for control over the nicotine dose is important. It argues not only for nicotine being a necessary condition for smoking but also that smokers are trying to obtain a dose which will produce desired or needed pharmacological effects. Before considering the range of these pharmacological effects of nicotine it should be pointed out that the titration evidence suggests low delivery cigarettes will not necessarily be safer because they are oversmoked and tar exposure will increase to medium delivery levels while the carbon monoxide levels can exceed those of high delivery cigarettes (Ashton and Telford, 1973). Lowering deliveries can only be done effectively when we understand more fully the cues and mechanisms that smokers use to adjust their nicotine intake.

1002973445

IV. NICOTINE PHARMACODYNAMICS

In this section we will discuss the actions of nicotine on the nervous system and on behaviour which may be used to account for the smoking habit. The literature is vast and so only illustrative experiments will be cited. In the first section the emphasis will be on the neurochemical changes that are produced by smoking doses of nicotine. In the second section the neurophysiological effects of nicotine will be outlined. In the third section these changes will be related to nicotine's effect on psychophysiological measures that have been associated with behaviour. The final, fourth section will discuss nicotine's action on human behaviour - the psychopharmacology of nicotine.

A. Neurochemical Action of Nicotine

Nicotine could modify neural transmission by interfering with one or more of the processes that are responsible for the regulation of transmitters i.e (1) Alter transmitter synthesis, by either changing the availability of transmitter precursors or changing the activity of the synthesising enzyme. (2) Interfere with the presynaptic storage of the transmitter. (3) Modify transmitter release into the synapse. (4) Alter the rate of transmitter inactivation by modifying the inactivating enzyme or the presynaptic reuptake (Warburton, 1975).

There is evidence in the literature from in vivo animal studies that nicotine produces changes in the brain levels of catecholamines, indoleamines and acetylcholine. The crucial questions are how can these changes in levels be related to the dynamics of transmitter systems and whether these changes can be extrapolated meaningfully to humans to explain the smoking habit.

A major problem, with the majority of these animal studies, is the unrealistically high dose levels of nicotine that have been tested. A 75 kg person, who takes between 0.75 and 3.0 mg of nicotine from a cigarette into his mouth, will receive a dose of between 10 and 40 µg per

1002973446

kg. This figure is close to that derived by Armitage (1974) who calculated that the dose inhaled from each puff by a smoker is equivalent to an intravenous injection of 1 to 2 μg per kg. Assuming about 10 to 20 puffs per cigarette, this will give a dose of between 10-40 μg per kg per cigarette. There will obviously be differences because of the route of administration (inhalation and intravenous injection versus subcutaneous and intraperitoneal injection) and the different metabolic rates of different species, but it is probably safe to conclude that in mice, rats or cats, any dose which is over 10 times this dose (0.4 mg/kg) is well outside the "smoking" dose range.

1. Catecholamines

Studies on the catecholamines, dopamine and noradrenalin have been carried out by Lichtensteiger and his co-workers (Lichtensteiger, Felix, Lienhart and Hefti, 1976; Lichtensteiger, Richards and Koppe, 1978; Lichtensteiger, 1979) by Fuxe and his colleagues (Fuxe, Agnati, Eneroth, Gustafson, Hokfelt, Lofstrom, Skett and Skett, 1977; Eneroth, Fuxe, Gustafson, Hokfelt, Lofstrom, Skett and Agnati, 1977 a and b) and Westfall's laboratory (Westfall, Fleming, Fudger and Clark, 1967; Westfall, 1974).

These studies have given the same general picture in spite of wide differences in nicotine dose levels, which ranged from 0.33 mg/kg in one of Lichtensteiger's studies to four doses of 3 mg/kg at 30 min intervals in one of the experiments of Fuxe's group. Lichtensteiger reported that the fluorescence intensity of both dopamine and noradrenalin neurones was increased in the substantia nigra nuclei, zona compacta and zona incerta with doses of 0.33 mg/kg and 1.00 mg/kg of nicotine, suggesting increased activity in these neurones. This conclusion was supported by microelectrode recording of the neurones and biochemical analysis which showed some depletion of both transmitters. Westfall has also found that dopamine was reduced in the striatum of the mouse after 1 mg/kg of nicotine injected intraperitoneally.

Lichtensteiger also reported increased fluorescence of dopamine neurones in the rat median eminence of the diencephalon after 1 mg/kg

1002973447

of nicotine and Westfall had previously found that this dose produced about 20 per cent depletion of noradrenalin in the same region in the mouse. Both of these findings would be consistent with increased neuronal activity in these catecholamine neurones and Lichtensteiger demonstrated, with microelectrodes, that there was increased neural activity in this region as well as decreased growth hormone and prolactin secretion in the blood stream (dopamine is thought to be involved in the secretion of these hormones). There was also some evidence which was compatible with nicotine activating dopamine neurones controlling luteinizing hormone release.

Fuxe and his group investigated the specific relation between nicotine, catecholamines and gonadotrophin secretion. Unfortunately, they used large doses of 1 mg/kg, 2 mg/kg and 3 mg/kg injected four times in 90 mins before sacrifice and assay. Nicotine produced a depletion of 25 per cent in catecholamine levels in the median palisade zone of the median eminence of male rats (Fuxe et al, 1977) but hexamethonium prevented depletion. No changes were found in dopamine or noradrenalin receptor activity in in vitro studies so the changes are secondary to effects on cholinergic neurones. They also observed a reduction of luteinizing hormone and prolactin secretion in female rats. The implication of these findings for human smoking is dubious due to the very high doses that were used and it would be quite wrong to conclude from this data alone that nicotine could produce hormonal problems in pregnant and lactating women who smoked.

2. Indoleamines

Changes in the concentration and turnover of serotonin have been found after doses of nicotine. A dose of 1 mg/kg of nicotine, intraperitoneally injected into mice, markedly increased the levels of serotonin in the mesencephalon and diencephalon within 15 mins but not in the cortex (Essman, 1971). In the same study serotonin's major metabolite, 5-hydroxyindoleacetic acid, was also increased but there was a decreased serotonin turnover rate of 20 per cent and increased serotonin turnover time (+300 per cent). These data are not simple to interpret but clearly with this moderately large dose there are increased serotonin levels in some brain regions

1002973448

probably due to increased synthesis and decreased release but, in spite of the decreased release, the large intraneuronal accumulation results in some leakage which elevates the level of 5-hydroxyindoleacetic acid. It is not clear whether the changes in serotonin after a moderately large dose of nicotine are important for human smoking.

3. Acetylcholine

Nicotine depletes whole brain acetylcholine in the rat (Pepeu, 1965) and mouse (Essman, 1971) in doses of 1 mg/kg. Depletion of transmitter could be a consequence of decreased synthesis, increased release from storage, increased release into the synaptic cleft or more effective enzymatic activation. There is no evidence that nicotine modifies acetylcholine synthesis (Hrdina, 1974) and the enzymatic inactivation of acetylcholine without any drug is extremely effective, which argues for a change in either storage or release. More importantly, there is strong evidence for increased free acetylcholine at the cortex after a "smoking" dose (40 µg/kg intravenously) in the cat (Armitage, Ball, Sellers, 1969) which is consistent with these two hypotheses.

The question of nicotine-induced changes in acetylcholine storage pools was tackled by Essman (1971). He found evidence of a decrease of acetylcholine in synaptic vesicles and in bound acetylcholine at the neocortex which suggests that acetylcholine was being released from storage by nicotine. However there was no increase in the free acetylcholine pool concentration which argues for increased release of the unbound transmitter and subsequent inactivation by acetylcholinesterase. The phenomenon of increased release at the cortex would be explained if nicotine enhanced presynaptic release mechanisms in cortical tissue but there is no *in vitro* evidence of enhancement (Hrdina, 1974). Thus we are left with the hypothesis that it is increased activity in the cholinergic neurones to the cortex which produces the *in vivo* depletion.

4. Conclusion

There is evidence that moderate to enormous doses of nicotine cause changes in catecholamines and indoleamines although the catecholamine changes were being mediated by cholinergic pathways. However, as

1002973449

Domino (1973) pointed out in a review of the behavioural studies, we must be cautious:- "The relevance of such large doses of nicotine given subcutaneously to the much smaller doses inhaled by man is certainly to be questioned" (P10).

The major effect with "smoking" doses has been to increase cortical release of acetylcholine but there is no evidence that release is due to a direct effect on the presynaptic release mechanisms of cortical neurones. One solution to the paradox lies in indirect activation of acetylcholine neurones which form part of the ascending cholinergic pathways to the cortex; this is discussed in the next section.

B. Neurophysiological Action of Nicotine

The action of many drugs has been explored by using the more readily accessible neurones in the peripheral nervous system which are more accessible than those in the central nervous system. Although caution must be exercised when using this data to explain central nervous system phenomena, in general, the principles that have been derived from such studies have proved useful in understanding the action of drugs on the brain. Thus the first studies will describe nicotine's action on these neural junctions.

1. Peripheral Nervous System

The action of nicotine on the nervous system has been known since the pioneering work of Dale who published a classic paper on acetylcholine "The action of certain esters and ethers of choline and their relation of muscarine" (Dale, 1914). This work established that nicotine mimicked the action of acetylcholine at autonomic ganglia and neuromuscular junctions and later it was established that acetylcholine was a transmitter at these synapses. Dale's work also revealed that some acetylcholine synapses, the post-ganglionic parasympathetic neurones, were better stimulated by muscarine than nicotine, and so it has become conventional to sub-divide peripheral nervous system neurones into "nicotinic" and "muscarinic" on the basis of their differential sensitivity to these two agonists - the two sorts of agonists that have been discovered. These neurones

1002973450

differ in the post-synaptic receptors as defined by Furchcott (1964):-
"The specific molecular sites in (or on) the effector cell with which the molecules of a specific agonist must react in order to elicit the characteristic response of the cell to the agonist". In the case of nicotine the characteristic response is postsynaptic depolarization.

The effects of different doses of nicotine on cell membrane depolarization and subsequent action potentials were compared by Paton and Perry, (1953) using the cervical ganglion preparation of the cat. The drug was injected into the external carotid artery and all branches of the common carotid were blocked except the arterial branches supplying the ganglion itself, and the occipital artery to allow free blood flow past the ganglion. Then 0.2 ml of the solution containing 50 μ g of nicotine tartrate was injected into the external carotid artery. This concentration is much larger than the 20-30 ng/ml found in the forearm vein after smoking (see Section II) but may be closer to the concentration ascending in the carotid artery after inhalation because none of this nicotine will have been metabolised. The effect of this dose was depolarization of the membrane and some reduction of the subsequent action potentials, a change which was similar to, but more transient than, the effects of a small dose of acetylcholine.

However 0.3 mg of nicotine, six times the above dose, produced prolonged depolarization and the action potentials were abolished ie ganglionic blocking. A challenge with a second dose of nicotine after the original depolarization, but before recovery of the action potentials, produced less depolarization than previously which demonstrated that nicotine was producing a competitive block of cholinergic receptors at very high doses. Exactly the same phenomenon has been observed with high doses of acetylcholine at the motor end-plate so that once again nicotine is mimicking acetylcholine. It has been suggested that the desensitization arises from the transformation of the acetylcholine receptor complex into an inactive form (Katz and Thesleff, 1957) and that the same effect occurs with nicotine. Whatever the reason, it seems unlikely that blood concentrations some 100,000 times that found in the human forearm vein ever occur in the smoker's brain and hence unlikely that a depolarization block occurs in brain neurones after nicotine. In summary, "smoking" doses of

1002973451

nicotine precisely mimic acetylcholine and produce the same neural changes that would occur after natural activation of that synapse.

The reason for the exact mimicking of acetylcholine by nicotine at some cholinergic synapses is the remarkable similarity between the structures of the two molecules. Analysis by X-ray diffraction crystallography has shown that in order to interact with nicotine receptors, a molecule must consist of a planar acetoxy group or an aromatic ring separated from a methylated ammonium group which is about 130 picometres above the plane of the planar group (Pauling, 1970). Nicotine does consist of a planar pyridine ring perpendicular to the four coplanar atoms of the pyrrolidine ring. Both nicotine and acetylcholine have a positively charged, methylated, tertiary nitrogen group (N^+-CH_3) in the pyrrolidine ring which in nicotine is attached to an electronegative, isosteric nitrogen in the pyridine ring at just the distance to match the electronegative carbonyl oxygen of acetylcholine (see Figure 1).


2. Adrenal Medulla

One preganglionic nerve, the lesser splanchnic nerve, continues without synapses to the medulla of the adrenal gland. The adrenal medulla can be considered as an aggregation of specialised postganglionic cells which releases catecholamines into the bloodstream instead of releasing noradrenalin at its terminals onto other organs. Adrenalin is the major hormone that is released into the circulation to act on target cells while noradrenalin is mainly a neurotransmitter although the plasma levels can rise to concentrations which produce hormonal effects, for example, after heavy exercise.

Both catecholamines trigger haemodynamic effects; both raise blood pressure and dilate coronary vessels but adrenalin alone dilates skeletal muscle vessels. The rise in blood pressure is due to vasoconstriction of vessels of the skin, mucous membranes and viscera. The catecholamines have no direct effect on blood flow in the brain although an adrenalin solution of high concentration produces a sudden rise in systolic and diastolic pressure which can cause cerebral haemorrhage. The

1002973452

NICOTINE AND ACETYLCHOLINE



1002973453

catecholamines have powerful effects on the heart increasing the shape of the pacemaker potential so that the firing threshold is reached more quickly and heart rate increases. It also increases the strength of heart rate contraction.



Of special interest are the metabolic effects of catecholamines. They accelerate delivery of glucose from the liver, reduce glucose clearance from the circulation and, as a consequence, the plasma levels of glucose rise. In addition the catecholamines stimulate lipolysis, increasing the delivery of free fatty acids to the liver. In the liver they may also act on hepatic metabolic processes to stimulate ketogenesis, which fuels those cells which do not depend on carbohydrates, and supplies glycerol for use in glucose synthesis. The increased free fatty acids will also reduce glucose uptake and use by cells with flexible metabolic requirements.

Classically these changes have been linked to the dramatic behaviour of flight or fight but the hormones have a much broader function. They are released when the person is anxious, concentrating hard, kissing or just changing from a lying down to sitting position; elevation of catecholamines does not necessarily indicate distress or unpleasant circumstances.


Smoking a single cigarette elevates both plasma noradrenalin and adrenalin within five minutes of starting the cigarette and they peak at, or soon after, the maximum plasma nicotine level is reached, see Figure 2 on page 39:

1002973454

Figure 2




Mean (\pm S.E.) plasma norepinephrine and epinephrine concentrations in association with smoking (closed symbols) and sham smoking (open symbols). The arrows indicate the period of smoking (or sham smoking).



Venous Plasma Levels of Epinephrine in Human Beings in Various Physiologic and Pathophysiologic States (Mean \pm S.E.M.).

Numbers in parentheses indicate the number of persons studied; solid circles represent the highest value observed. Dashed lines indicate the ranges of concentrations required to produce measurable changes in heart rate, systolic blood pressure, and blood glucose (about 50 to 100 pg per milliliter), increases in plasma glucose, blood lactate, blood beta-hydroxybutyrate, and diastolic blood pressure (about 150 to 200 pg per milliliter), and initial decreases in plasma insulin (more than 400 pg per milliliter) in normal human subjects.⁶



Venous Plasma Levels of Norepinephrine in Various Physiologic and Pathophysiologic States in Human Beings (Mean \pm S.E.M.).

Numbers in parentheses indicate the number of persons studied; solid circles represent the highest value observed. Dashed lines encompass the range of concentrations required to produce measurable metabolic and hemodynamic changes in normal subjects.⁷

1002973455

The peak plasma concentration for noradrenalin is 330-350 pg/ml and for adrenalin it is 100-140 pg/ml (Cryer, Haymond, Santiago and Shah, 1976). These levels must be considered in the context of the levels for other activities (Cryer, 1980). It can be seen that cigarette smoking produces higher levels of noradrenalin than resting supine, but less than quiet standing and mild exercise and certainly less than moderate and vigorous exercise. A slightly different pattern is seen with adrenalin levels after smoking; they are about the same as after moderate exercise and greater than resting supine, quiet standing and mild exercise, but about a quarter of the levels seen after heavy exercise, over 400 pg/ml. Cryer (1980) has used graded infusions of noradrenalin and adrenalin to discover the threshold levels for haemodynamic and metabolic changes and found that smoking produces suprathreshold elevations of adrenalin but not noradrenalin. The adrenalin thresholds were 50-100 pg/ml for increased heart rate, 75-125 pg/ml for systolic pressor effects and lipolysis and 150-200 pg/ml for ketogenesis and glycolysis changes (see Figure 2).

In summary, nicotine, from a single cigarette, produces small increases in plasma catecholamines which just exceed the threshold for cardiovascular and some metabolic effects. It should be noted that "not only are noradrenalin and adrenalin rapidly cleared but they also accelerate their own metabolic clearance" (Cryer, 1980; P438) so that only very heavy smoking would produce accumulations of adrenalin and measurable metabolic effects. For example, in order to demonstrate that cigarette smoking could produce an increase in plasma free fatty acids and so contribute to coronary heart disease, atherogenesis, and atherosclerosis, Kershbaum and Bellet (1968) resorted to giving three cigarettes in 20 mins ie chain smoking. The lack of realism of this dose can be seen from the fact that if sleeping took up eight hours and three hours were spent eating (generous assumptions) then a 40 a day smoker would have a cigarette every 20 mins. For average smokers the effect of nicotine on the adrenal medulla is no more than taking moderate exercise. The fatigue alleviation that would result from the metabolic changes will be discussed at the end of the next sub-section on nicotine and the adrenal cortex.

1002973456

3. Adrenal Cortex

The outer region of the adrenal gland is the adrenal cortex which contains zones of cells secreting hormones. The zona fasciculata and zona reticularis secrete the glucocorticoids of which the two most important, in humans, are cortisol and corticosterone. Unlike the adrenal medulla, release of hormones from the adrenal cortex into the circulation is controlled from the brain, via the release of adrenocorticotrophic hormone from the anterior pituitary, and not by the autonomic nervous system.

However the glucocorticoids like the catecholamines have marked metabolic effects but small or no haemodynamic action. They are essential for the mobilization of tissue proteins and for transferring the derived amino acids to the liver. The liver glycogen stores are limited and amino acids provide the major source of energy supply. In the liver, the glucocorticoids promote synthesis of enzymes that are used in gluconeogenesis. As well as conversion of amino acids to glucose, they also speed up extensive mobilization of depot lipid reserves, inhibit lipid synthesis and reduce glucose catabolism. Together these effects elevate plasma concentrations of glucose.

The glucocorticoids increase cardiac output and exert a "permissive action" on the cardiovascular effects of catecholamines in the sense that catecholamine vasoconstrictor responses are diminished when there are insufficient glucocorticoids. The two sets of hormones seem to be released in the same sort of circumstances, eg in response to stressors and when a person is concentrating. At the moment it is not clear what affects the different patterns of catecholamine and glucocorticoid release. Certainly, the two sets of hormones mobilize energy sources and prepare the person for action and reduce fatigue. The neural activation of the catecholamines ensures a rapid response, while the hormonal activation of the glucocorticoids results in a delayed, but more prolonged, action.

Adrenocortical secretion does increase after smoking although it does not seem to occur after only one cigarette. Kershbaum made habitual smokers chain smoke four unspecified cigarettes in thirty minutes and

1002973457


took plasma samples at 30 mins and 90 mins (Kershbaum, Pappajohn, Bellet, Hirabayashi and Shafiiha, 1968). The plasma corticosteroid levels were markedly elevated after 30 mins and still above baseline at 90 mins. In the commentary Kershbaum mentions that there was some release (range 22 to 46 per cent) when "Two cigarettes were smoked by each of several subjects" but no further details were given.

In a second study, habitual smokers were given 8 high nicotine (2.5 mg) cigarettes to smoke in a two hour session (equivalent to over 100 cigarettes per day; Winternitz and Quillen, 1977). According to the authors "A sharp rise in plasma cortisol occurred after two cigarettes which was maintained through the 2nd hour and fell slowly after the smoking period" (P396). In fact their graph (Figure 3) shows that cortisol levels are the same or lower after the second cigarette and it is after the third cigarette in half an hour that cortisol had increased. Only continual smoking increased the plasma cortisol concentration and maintained it above baseline levels for the two hours. The best conclusion that can be drawn from these studies is that high nicotine doses from exaggerated smoking rates can elevate plasma glucocorticoids. An alternative interpretation is that the rapid smoking was aversive and stressed the subjects. Incidentally, the US Surgeon General's Report (1979) only cites the preliminary study of Winternitz and Quillen in which non-smokers smoked six cigarettes in two hours, were sick and had increased adrenocorticotrophic hormone levels.

If we accept the most charitable interpretation that smoking produces some release of glucocorticoids from the adrenal cortex then these hormones, combined with the catecholamine release, will make available energy sources for use by the brain and the rest of the body. In this way smoking would alleviate mental and muscle fatigue. Studies of carbohydrate and lipid use in physical work of different intensities have found that during exhausting work there was a depletion of carbohydrates, but subjective symptoms of fatigue disappeared within 15 min of ingesting glucose which increased the blood-sugar levels again (Christensen and Hansen, 1939). The central nervous system has low reserves of glucose and depends on blood carbohydrate for its supply of energy. In man about 60 per cent of the liver glucose output supplies brain metabolism, and so exhaustion

1002973458

Figure 3



seems to be as much a central nervous phenomenon as is lack of sugar for muscles peripherally (Åstrand and Rodahl, 1970).

It has been suggested that the elevation of blood glucose could be responsible for the satisfaction derived from smoking because glucose would activate the reward pathways in the hypothalamus (Surgeon General, 1979). Carruthers (1975) used oxprenolol to block the responses to catecholamines release by smoking i.e. free fatty acid mobilization, blood pressure and heart rate increases. The subjective reports indicated no effect on satisfaction after smoking, which rules out the involvement of blood glucose (and blood pressure and heart rate increase) in satisfaction. It seems more likely that satisfaction is the outcome of the changes in the central nervous system.

4. Central Nervous System

The first evidence for "nicotinic" receptors in the central nervous system came from studies of the Renshaw cell in the spinal cord (Eccles, Eccles and Fatt, 1956). It was shown that, when either 200 µg of acetylcholine or 1 µg of nicotine were injected close to the cell an action potential was produced. The response to nicotine was the same as that to acetylcholine but more prolonged because, unlike acetylcholine, it was not inactivated by acetylcholinesterase. When acetylcholinesterase was inhibited by physostigmine, acetylcholine produced a much larger response, but the response to nicotine was unchanged, which showed that nicotine's effect was directly on the post-synaptic receptors of the Renshaw cell and not via the release of acetylcholine. Nicotine antagonists reduced the response to both acetylcholine and nicotine, also indicating that nicotine was acting directly on cholinergic synapses. Many studies have now shown that there are nicotinic receptors on this cell although there seem to be muscarinic and even mixed synapses as well (Curtis and Ryall, 1966).

Studies with iontophoretically applied acetylcholine have revealed that this transmitter excites neurones in many regions of the brain (Phillis, 1970) including the medullary and mesencephalic reticular

1002973460

formation, lateral and medial geniculate, caudate nucleus, ventrobasal complex of the thalamus, hippocampus, cerebellum, inferior colliculus and the Betz cells of the deep pyramidal layer of the cerebral cortex. Cortical cells and caudate nucleus cells clearly have muscarinic receptors which were relatively insensitive to nicotine while acetylcholine receptors in the geniculate nuclei, ventrobasal thalamus, hippocampus and reticular formation nuclei were sensitive to both nicotinic and muscarinic drugs. Cholinergic inhibitory neurones, with mixed nicotine and muscarinic receptors, have been found at the cortex in layers II, III and IV of the primary sensorimotor auditory and visual areas.

In spite of the clear evidence that the cholinergic neurones at the cortex are predominantly muscarinic, "smoking" doses of nicotine (eg 20 $\mu\text{g/kg}$ in the cat) produce excitation of cortical cells (Knapp and Domino, 1962; Kawamura and Domino, 1969; Armitage, Hall and Sellers, 1969) and release of acetylcholine at the cortex (Armitage et al, 1969). In the study of Kawamura and Domino (1969) blood pressure was kept constant with drugs, so that the effect was not due to vascular changes.

Cortical acetylcholine release and cortical excitation can be produced by stimulation of the mesencephalic reticular formation and this phenomenon can be reduced in one hemisphere by unilateral destruction of this region ipsilaterally (Celesia and Jasper, 1966). In a neuropharmacological analysis of the effects of "smoking" doses of nicotine after destruction of the midbrain (Domino, 1967; Kawamura and Domino, 1969), 20 $\mu\text{g/kg}$ of nicotine produced cortical desynchronization and hippocampal synchronization in cats with a caudal midbrain transection at the junction of the pons in exactly the same way as intact animals given nicotine. After bilateral lesions in the tegmental region of the midbrain, nicotine in doses up to five times the 20 $\mu\text{g/kg}$ "smoking" dose did not activate the cortex. Clearly, nicotine's action on the cortex depends on an intact tegmental region. The ventral tegmental region of the mesencephalic reticular formation is the origin of a cholinergic pathway which projects to the cortex (Shute and Lewis, 1967) and there is good evidence that it terminates on the pyramidal Betz cells at the sensory cortex and produces electrocortical arousal (see review by Warburton, 1981).

1002973461

The most parsimonious conclusion is that "smoking" doses of nicotine ascend in the carotid artery and excite nicotinic receptors on the tegmental-neocortical cholinergic pathway in the midbrain. Nicotine does not act directly on the cortex but the outcome of activation of the pathway at the midbrain is release of acetylcholine at the cortex and cortical desynchronization.

C. Nicotine and Human Psychophysiology

In this section we will consider the action of nicotine on the human cortex in the context of psychophysiology, the correlation of neurophysiological events with human behaviour. The first part will consider the effects of nicotine on cortical desynchronization, the second part will outline nicotine's action on the contingent negative variation while the third part will discuss event related potentials. The methodology of this research has been critically reviewed by Edwards (submitted for publication).

1. Cortical Desynchronization

Electrocortical activity is recorded by scalp electrodes which enable the measurement of the composite activity of cortical cells through the skull and scalp. When the firing of cells is synchronized, as they are during some periods of sleep, the electroencephalogram (EEG) shows low frequency ($\frac{1}{2}$ - 5 Hz), large amplitude (ie high voltage) waves (delta waves). When a person wakes and becomes alert, the waves decrease in amplitude and increase in frequency through theta waves (4 - 7 Hz), alpha waves (8-12 Hz) to beta waves (13 - 50 Hz). A high proportion of beta activity, cortical desynchronization, is correlated with a state of full alertness and concentration in the person while a high proportion of alpha activity is correlated with relaxed wakefulness.

Many human studies have shown that smoking increases the amount of cortical desynchronization in the form of an upward shift in dominant alpha frequency ie more 10 - 12 Hz (eg Hauser, Schwartz, Roth and Bickford, 1958), less total alpha activity and more beta activity (eg Knott, 1979; Murphree, 1979). Thus these human studies show that smoking

1002973462

produces cortical desynchronization just as nicotine does in animal studies. In a study correlating performance with electrocortical activity, Warburton and Wesnes (1979) found that both cigarettes and nicotine-tablets increased the dominant alpha frequency (11.5 - 13.5 Hz) and beta activity (13.5 - 20 Hz).

In the same study, performance on a task involving concentration was improved by the same treatments. Many other studies at Reading University have confirmed that smoking and nicotine tablets, given to smokers and non-smokers, improve performance in tasks requiring sustained concentration (eg Wesnes and Warburton, 1978; 1982). In none of these studies were there differences in the effect of nicotine on performance in smokers and non-smokers. Therefore, it is significant that Murphree (1979) was unable to find any differences in the cortical desynchronization of smokers, who smoked at least 10 cigarettes per day, and non-smokers produced by an intravenous nicotine dose of 1.86 mg, a "smoking" dose. In other words, the smokers responded in the same way as non-smokers and there was no evidence of tolerance to nicotine's effect on electrocortical activity. These results make sense because of the molecular similarity of nicotine and acetylcholine. The brain cannot become tolerant to its own transmitters, and as nicotine is similar enough to acetylcholine, tolerance does not develop to nicotine either. This lack of tolerance to nicotine explains why smokers do not increase their consumption of cigarettes over the years (apart from compensating for any decrease in average nicotine - see page 90).

In concluding this illustrative review of nicotine's action on cortical desynchronization, it must be emphasised that the shifts produced by nicotine are within normal limits ie they are indistinguishable from those that occur when a person is concentrating hard. There is certainly no evidence of the EEG abnormalities that occur with other psychostimulants eg amphetamine. Smokers claim that they smoke to help them think and concentrate and nicotine's action on cortical desynchronization produces the neural state for satisfying this need. Evidence that smokers can control their nicotine intake to produce a specific brain state has come from contingent negative variation studies.

1002973463

2. Contingent Negative Variation

The contingent negative variation (CNV) appears as a slow negative shift of cortical potential during the period between a warning signal and an imperative stimulus which requires a motor response or a decision. Thus, the CNV represents a cortical change associated with planned action before a response to a sequence of two or more events. Significant correlations have been reported between CNV amplitude and measures said to represent selective attention, arousal, motivation, anticipated energy output, conation, orientation, expectancy, and preparation for action, but selective attention or concentration is the most commonly used concept.

Experiments on the CNV and smoking (Ashton, Millman, Telford and Thompson, 1974; 1976; Ashton, Marsh, Millman, Rawlins, Telford and Thompson, 1978; Comer, Binnie, Burnett, Darby and Thornton, 1975; Binnie and Comer, 1978) have correlated CNV with subjective reports of feeling either "relaxed" or "stimulated" following smoking. Ashton collected personality information and estimated (by analysis of the cigarette butt) the amount of nicotine taken into each subject's mouth. After smoking, CNV amplitude increased in seven subjects, decreased in eleven and showed a biphasic response in four (Ashton et al, 1974). "Smoking" an unlit cigarette by three other subjects resulted in no CNV amplitude changes. Repetition of the smoking sessions for eleven of the subjects, on a different occasion, produced the same directional changes in the CNV in these individuals.

Ashton and her co-workers argue that the origin of the CNV is in the ascending reticular activating system and probably the limbic system and they assume that there is a positive relationship between CNV magnitude, activity in these systems and the individual's level of stimulation. Data from drug studies support these assumptions: CNV magnitude increased after doses of the psychostimulant caffeine and CNV magnitude decreased following oral doses of the sedative, diazepam (Valium) (Ashton et al, 1974; 1978).

Ashton et al related individual differences in CNV to personality and smoking behaviour. By dividing their group at the extraversion mean they

1002973464

found that the eight more extraverted subjects took a smaller oral dose of nicotine per minute and showed a mean increase in CNV magnitude after smoking, while the eight more introverted subjects showed the reverse. They attempted to analyse subjective experiences of smoking but these did not provide clear data. However, there was some evidence from subjects that self-report of a "sedative" effect of smoking was associated with a fall in CNV whereas "stimulation" was associated with a rise in CNV.

Ashton and her co-workers (1978) also examined the effects of intravenous nicotine. They gave discrete pulses of nicotine to provide a total dose similar to that obtained by a smoker who inhales a cigarette delivering 1 - 2 mg of nicotine. The same direction of change in CNV occurred in individuals who took part in both smoking and nicotine sessions. Saline injections produced no significant changes. As a further refinement, Ashton et al (1978) examined the question of whether the CNV changes are dependent on the dose of nicotine or, alternatively, on the characteristics of the smoker and, therefore, largely independent of dose. Over a range of doses, from 12.5 - 800 μ g, there was an inverted U relation between CNV magnitude and dose; with lower doses (12.5 - 50 μ g) the CNV increased as the dose increased, but with further increases (100 - 800 μ g) there was a progressive reduction in CNV magnitude. This pattern was evident for all seven subjects although the precise dose-response relation was not the same for each of them.

In summary, smoking and nicotine produced similar changes in the CNV in the same person. Nicotine increased or decreased the CNV amplitude depending on the dose and subjects seemed to control their smoking behaviour in order to obtain a particular dose. These findings were combined by Ashton to give the hypothesis that individuals adjust their smoking behaviour to the amount of nicotine for a particular brain state and so control their psychological state. The desired state will depend on the outcome of interaction between the individual and the situation and, by adjusting the nicotine dose, the same individual may use a cigarette to provide a stimulant effect on one occasion and a depressant effect on another.

1002973465

3. Event-Related Potentials (ERP)

Event-Related Potentials, sometimes known as Averaged Evoked Potentials, are the complex electrical changes recorded at the same time as a physical or mental event and represent the activity of groups of neurones in the brain. The obvious advantage of the ERP technique is that it provides a continuous record of events occurring in the brain during psychological processes. The problem with recording the electrical activity from the scalp associated with a single event is that it is too small to detect against the background of cortical desynchronization and so "signal averaging" techniques are employed to distinguish ERP's from the obscuring background activity. If the ERP is the same with every event then it will become more and more recognizable against the random EEG noise during the averaging process.

With repetitive stimulation, the post-stimulus waveform between 0 to 250 msec consists of components which are essentially constant in amplitude, latency and scalp site distribution for a given stimulus. These exogenous components occur whether the subjects attend or not, are awake or asleep, aroused or relaxed. Of particular interest are the so-called endogenous components which are emitted or elicited, often in the absence of stimulation, and whose characteristics are partially independent of the physical characteristics of stimuli. The major endogenous component which has been identified is the P₃ or P300 whose latency ranges from 275 - 600 msec. The P300 is particularly sensitive to the subject's prior experience, intentions and decisions and varies according to the task requirements and experimental instructions.

A recent experiment (Edwards, Wesnes, Warburton and Gale, in preparation) enabled an analysis to be made of the effects of smoking on the ERPs to correct target detections in a rapid information processing task. In this test subjects were instructed to detect and respond to triplets of three odd or even digits in a sequence of single numbers that were presented on a TV screen at the rate of 100 per minute. Good performance depended on subjects maintaining their concentration throughout the 20 minute session. Preliminary analysis has shown that smoking produced large decreases in the latency of P300 (20-30 msec decrease) and small decreases in the amplitude of P300. A reduction in P300

1002973466

latency is interpreted as a decrease in the time taken to evaluate or categorise a stimulus while a decrease in P300 amplitude is thought to mean that the subject is using less neural "resources" in processing. For example, when the probability of a signal is high then the amplitude is smaller than when the stimulus is novel because the information needs less analysis by the brain. Analysis of the performance showed that smoking increased the targets detected and decreased the reaction time (see sub-section IV D). This improvement of performance fits neatly with the P300 changes which are indicative of more efficient neural processing of the stimulus.

D. Psychopharmacology of Nicotine

In this section evidence will be presented on the implications for human behaviour of the neural states that are induced by nicotine. As we have seen, nicotine stimulates and produces increased neural efficiency. There is also evidence that nicotine can produce neural changes that have been interpreted as a sedation effect. Questionnaire surveys (eg McKennell, 1970; Thomas, 1973; Russell, Peto and Patel, 1974) have shown that a desire for stimulation and a desire for sedation are two of the major motives for smoking for a majority of smokers. Accordingly, this section will concentrate on the evidence for more efficient performance after nicotine and the effects of nicotine on mood states.

1. Performance

There are many possible tests of human performance which are sensitive to drugs, but a major problem is interpreting the data in terms of the psychological processes which are modified. These include (1) sensation (the input of information); (2) attention (selection of information); (3) processing of information; (4) learning and memory (storage of information); and (5) motor output (the response). Ideally, experiments are designed to study one process by minimising the influence of others on performance.

1002973467

The earliest of the acceptable studies was done by Hull (1924). He used a within subject design and compared the effects on performance of tobacco smoke from a pipe and of moistened hot air. He measured several physiological variables and increases in heart rate indicated that subjects were absorbing nicotine from the tobacco smoke so it is reasonable to attribute the effects of smoking to nicotine. Nicotine improved reaction time and increased the speed but not accuracy of mental addition but impaired rote learning and memory span. In general, experienced smokers were more affected than non-smokers, suggesting that they had absorbed more nicotine from the tobacco smoke, probably by inhalation. This evidence suggests that nicotine is increasing information processing speed but interfering with information storage. However, it is not possible to rule out the explanation that the faster reaction was due to improved attention to the stimulus or the possibility that the impaired information storage was due to interference with the sensory input.

a. Sensation

There is little evidence from subjective reports of smokers that smoking has any effect on the ability to receive information from the environment, except perhaps for possible blunting of taste and smell. So it is not surprising that there is no confirmed evidence that nicotine significantly facilitates or impairs this process, although some research suggests that smoking raises sensory thresholds slightly ie the smokers are less sensitive to stimuli (Larson, Haag and Silvette, 1961). However, there are also reports that smoking doses of carbon monoxide increase brightness thresholds by about 3 per cent (Halperin, McFarland, Niven and Roughton, 1959) which would explain the small changes in threshold that were produced by smokers. Even for taste the evidence for changes after smoking are not clear cut. Pangborn and Trabue (1973) reviewed 16 experimental studies between 1937 and 1970 of which 11 reported impaired taste and/or smell with heavy smoking, and 5 which found no difference or negligible changes in sensitivity. The effects of nicotine alone on sensory thresholds have not been studied.

1002973468

A second test, which has been used to assess the effects of smoking on sensation, is the critical flicker fusion test. Briefly, this task requires the subject to discriminate between intermittent photic stimulation which either appears to flicker or appears to be a steady light. The dependent variable is the frequency of flashes at which the change in appearance occurs. A rise in threshold could indicate better sensory processing. A comparison of smokers deprived since the previous night with deprived smokers, who were allowed to smoke a cigarette before testing, showed that smoking increased the threshold slightly (Larson, Finnegan and Haag, 1950). A later study tested a small oral dose of 0.1 mg of nicotine in the form of tobacco powder (Warwick and Eysenck, 1963) and found an elevation of the fusion threshold by about seven per cent. The importance of these changes is difficult to interpret because the finding cannot be related to real life situations. It is believed that the mechanism for critical flicker fusion is at the cortex because alternate flashes to both eyes will produce fusion and so Warwick and Eysenck claim that it is a measure of cortical reactivity rather than sensory processing. In the next section we will be considering the process of attention which is also related to cortical arousal.

In summary, there is little direct or indirect evidence that nicotine improves or impairs sensation to an extent for which it is of practical significance.

b. Attention

Subjective reports from smoking motive questionnaires (eg Russell, Peto and Patel, 1974) indicate clearly that smokers believe that smoking helps them to think and to concentrate. The first piece of experimental evidence to suggest that this experience of enhanced concentration was due to nicotine came from a complex vigilance study by Tarrière and Hartemann (1964) in which subjects performed a main guiding task with a subsidiary visual monitoring task. They counted correct detections of peripheral signals, false detections and guidance errors and said that they measured plasma nicotine and several physiological variables including heart rate and EEG. The test

1002973469

groups were non-smokers, smokers deprived for 20 hours and smokers allowed to smoke unspecified cigarettes whenever they wished. Unfortunately they do not give the plasma nicotine levels and their section and graph of "level of nicotine" refers to carbon monoxide. No EEG data are given but an elevation of heart rate, after smoking, indicates some nicotine absorption. Vigilance performance, which was measured in terms of percent omissions, declined in non-smokers and deprived smokers during the 150 minute test but nicotine maintained detection performance throughout the session. No other behavioural data were given on detection errors or guidance errors, presumably because they did not change, but in view of the mistakes in the paper we cannot be certain about this lack of effect. If performance detection had been maintained at the expense of guidance then we could not conclude that concentration was enhanced.

Results which were consistent with Tarrière and Barmann's study were outlined in a report of smoking and simulated driving (Heimstra, Bancroft and DeKock, 1967). The study will only be mentioned briefly because no physiological measures were taken so the effect of smoking on performance cannot be attributed to nicotine. Heimstra et al studied the effects of smoking and smoking deprivation on brake light vigilance, meter vigilance, steering and brake pedal reaction time. Three groups were used: non-smokers, smokers who were deprived for the six hour test and smokers who could smoke as much as they wished. The consequences of smoking were better performance in comparison with deprived smokers; this effect was manifested as prevention of performance deterioration rather than a performance improvement above control levels.

Frankenhaeuser and her colleagues (Frankenhaeuser, Myrsten, Post and Johansson, 1971) also found that smoking during a prolonged reaction time task enabled subjects to maintain their performance. All subjects were deprived of cigarettes for 10 hours prior to testing. Half of them remained deprived throughout the test while the other half were allowed a 1.4 mg nicotine cigarette after 20 mins, 40 mins and 60 mins of testing. Heart rate increases confirmed that nicotine had been absorbed and the urinary adrenalin levels of the smokers were higher.

1002973470

The reaction times for the deprived smokers increased during the course of the 80 minute session while smoking maintained the reaction time. As a group, the smokers also reported that they felt more alert and more relaxed when smoking.

Essentially, the same findings were obtained when the study was repeated using either a similar prolonged test - a low arousal test, or a similar test but with the added stress of two other tasks to be performed at the same time - a high arousal test (Myrsten, Post, Frankenhaeuser and Johansson, 1972, Myrsten, Andersson, Frankenhaeuser and Mardh, 1972). The smokers were sub-divided, on the basis of a questionnaire, into smokers who smoked more often in low arousal situations and those who smoked more often in high arousal situations. Reaction times were better for low arousal smokers who smoked during the low arousal test than when they were deprived but smoking was not beneficial during the high arousal test. The opposite finding was obtained for the high arousal smokers; they only improved with nicotine in the high arousal test. These two studies were the first to reveal that performance was the outcome of a smoking x individual x situation interaction.

In studies at Reading University (Wesnes and Warburton, 1978) smokers deprived for 12 hours and non-smokers were tested on a visual vigilance task which consisted of detecting brief pauses in the minute hand of a clock. Detection performance declined over the 80 minute test in all subjects who did not smoke but deprived smokers who smoked a 1.4 mg cigarette at 20 mins, 40 mins and 60 mins (as in the Frankenhaeuser studies) showed no decrement in detection performance. This experiment revealed that cigarettes helped smokers to maintain better detection performance than either deprived smokers or non-smokers. The two non-smoking groups did not differ significantly so there was no evidence that cigarette deprivation was an important factor. Evidence that this effect was due to nicotine came from a second study with this task using 0, 1 and 2 mg nicotine on alkaline tablets held in the mouth, which enabled buccal absorption of nicotine (Russell and Wesnes, unpublished). The tablets were given to smokers after the same 20 minute intervals as before, in a repeated measure design. During

1002973471

the first 20 minutes, performance in the three conditions was matched to give a baseline and a comparison of the three conditions showed a clear dose related improvement after the first and second tablets at 20 mins and 40 mins. However, after the third tablet at 60 mins, performance was worse in the 2 mg group than the 1 mg group. This difference was probably due to the toxic effects of the cumulative dose of 6 mg of nicotine in an hour.

In a third study, cigarettes yielding 0.31, 0.71, and 1.65 mg of nicotine were compared using a version of the vigilance task, with well defined detection intervals and the same experimental design as before. The cigarette butts were analysed to estimate the amount of nicotine which was generated by the smoker. The best group performance, during the first 20 minutes after a cigarette, was obtained after smoking the 0.71 mg nicotine cigarette rather than after smoking the 0.31 mg nicotine cigarette. However, the butt analyses showed that smokers obtained estimated mouth levels of 0.63 mg of nicotine from the 0.31 mg nicotine cigarette, 1.3 mg nicotine from the 0.71 mg nicotine cigarette and 1.5 mg nicotine from the 1.65 mg nicotine cigarette giving evidence of titration. Analyses of individual differences gave clear evidence that subjects who scored high on neuroticism smoked harder at the beginning of the session than low neuroticism subjects while there was some evidence that subjects who scored high on extraversion smoked more intensely at the end of the session than the more introverted subjects. The performance data showed that smoking produced most improvement in subjects with high neuroticism scores. An individual difference analysis of the nicotine tablet study, that was described above, gave similar evidence. Once again, these studies suggest that subjects had a need for nicotine to help them perform within the experimental situation. This need determined the smoking behaviour and performance was the outcome of the interaction of the situation, the individual and smoking.

As well as examining the effects of nicotine and smoking in a long boring task we have also examined sustained attention in a shorter 20 minute rapid information processing test. In a set of eight studies (see Wesnes and Warburton, 1978 and in press) we have tested

1002973472

cigarettes of different nicotine deliveries ranging from 0 mg (herbal cigarette) to 2 mg as well as nicotine tablets. The test consisted of a random series of digits, presented individually on a TV screen, at a rate of 100 per min and subjects were asked to respond if they saw a sequence of three odd or three even digits. Eight of these triplets were presented every 10 minutes. Each subject was tested for 10 minutes before a further 20 minutes after a cigarette or tablet. Performance was compared with both the pre-drug baseline and the no smoking, herbal cigarette or placebo tablet conditions. Rather than discuss each individual study only the overall pattern of the findings will be presented. During the three control conditions performance declined over the 20 minute session, in exactly the same way for herbal cigarettes and no smoking, showing that the smoking act itself had no influence on performance in terms of correct detections.

Smoking not only improved performance relative to not smoking but produced an absolute enhancement relative to the pre-nicotine baseline in the first 10 minutes. The absolute enhancement was 11 - 14.5 per cent better than baseline and occurred in 68 - 75.5 per cent of the subjects for each cigarette in each study. In general, a greater improvement was seen after high delivery cigarettes than low delivery products but there was overlap between cigarettes of similar delivery probably due to nicotine titration by the subjects. Conclusive evidence that the better detection performance was due to nicotine came from a study with non smokers using alkaline tablets containing nicotine (Wesnes and Warburton, in press). Doses of 0.5, 1.0 and 1.5 mg of nicotine significantly reduced the decrement of detection that occurred in the placebo condition and the 1.5 mg dose produced a significant absolute improvement relative to the pre-drug baseline. In this task the stimuli were well above threshold, the memory component was small and the motor response was a simple button press so it can be concluded that nicotine was enhancing either the attentional process, information processing, or both processes.

Support for enhancement of the attentional process comes from a study of nicotine tablets and the Stroop effect. In the Stroop test, subjects name the colours of a set of colour spots and then they are

1002973473

presented with a set of colour words printed in another colour. There is a difference between the time taken to read the two sets, known as the Stroop effect, because of the distractions produced by the incongruity between print colour and colour word. Nicotine doses of 1 mg and 2 mg reduced the magnitude of the Stroop effect in both smokers and non-smokers and there was no difference in the size of the effect in smokers and non-smokers. This evidence argues strongly for the hypothesis that nicotine helps a subject to ignore distracting information and concentrate on relevant information.

In summary, this body of data supports the subjective experience of smokers that smoking helps them to concentrate. Correlative physiological and biochemical data together with the nicotine tablet studies indicate that nicotine in cigarette smoke is the agent responsible for this effect. As we have seen, nicotine increases electrocortical arousal and so this work fits neatly with research demonstrating that drugs which modify electrocortical arousal change attentional performance; increases in electrocortical arousal enhance attentional filtering while decreases impair this process. (see review Warburton, 1981). In this way nicotine enables subjects to sustain their concentration and filter out distractions.

c. Information Processing

Some evidence for more efficient processing with nicotine came from the early study of Hull (1924) who demonstrated that nicotine, from pipe smoke, decreased reaction time and improved addition speed. This finding was supported by a study of cigarette smoking and simple reaction time (Fisher, 1927). It could be argued that, in simple reaction time studies where subjects only have to decide if a light is present, the information processing component is small, but faster addition without loss of accuracy would seem to support the hypothesis of greater processing efficiency.

The studies of smoking and nicotine tablets and rapid information processing (Wesnes and Warburton, in press) provide unequivocal evidence for more efficient processing when using cigarettes or tablets with nicotine. As we have seen, both cigarette smoking and nicotine tablets

1002973474

improved detection of the triplets of three odd or three even digits in a string of single numbers flashed on a computer screen. The reaction times of these detections were also recorded and it was found that nicotine from cigarettes and tablets reduced reaction time. The reaction time improvement was around seven per cent and between 65 and 77 per cent of the subjects were improved depending on the nicotine delivery of the cigarette. This finding is very important because it shows that there is no trade-off between speed and accuracy and there was an overall improvement in processing efficiency.

This behavioural data fits neatly with the study of Edwards *et al* (in press) which showed that smoking decreased the latency and amplitude of the P300 wave of the event related potentials in the rapid information processing task that was referred to previously in Sub-section IV C3. In this study the behavioural data also showed faster reaction time and improved detection of the odd and even triplets of digits. Thus both behavioural and electrocortical measures indicate that nicotine is enabling more efficient processing of information in the brain.

In summary, the evidence from this section and the last section are consistent in showing that nicotine by its action at the cortex of the smoker produces better information selection and faster, more accurate evaluation of that information.

d. Learning and Memory

The effects of nicotine on learning have been investigated most extensively by Karin Andersson. The first study, (Andersson and Post, 1974) compared the effect of nicotine-free cigarettes and nicotine cigarettes on learning a nonsense syllable list on light smokers (less than five per day) who were deprived for 12 hours prior to the testing. On the first test day subjects always smoked a 2.1 mg nicotine cigarette and on the second day subjects were given a nicotine-free cigarette. Significant increases in heart rate showed that the subjects were absorbing nicotine from the nicotine cigarettes. The first cigarette was given after the first ten trials of learning the list of nonsense syllables and a second cigarette, of the same

1002973475

kind, was given after 20 trials; trials were given every two minutes. The learning curves were identical for the two conditions prior to smoking, but after smoking, the number of correct syllables decreased when the subjects had the nicotine cigarette and remained below the performance in the nicotine-free condition although the learning curves were parallel. After the second nicotine cigarette, the number of syllables correctly repeated increased significantly and reached the same level of acquisition performance as in the nicotine-free cigarette condition. Thus, relative to the previous performance, nicotine had improved recall of the syllables. These data give no evidence of nicotine impairing learning because the learning curves are parallel after the nicotine cigarette. It was as if the information stored in the non-nicotine state was less available in the drug state, a phenomenon known as state-dependent learning. We will return to tests of this possibility later.

In a related study using nonsense syllables (Andarsson, 1975 a) a similar learning procedure was used in which subjects smoked either a high nicotine cigarette (2.1 mg) or did not smoke after the tenth trial. Heart rate changes indicated nicotine absorption in the smoking condition. After trial 20 there was an interval of either 8 minutes or 45 minutes when subjects were given a jigsaw puzzle to solve to prevent rehearsal. Then, a single recall trial was given 28 or 65 minutes after smoking. Performance on trials 1-10 were the same for the smoking and no smoking conditions, nicotine decreased recall on trials 11-20 although did not affect the rate of acquisition. After 8 minutes there was poorer recall in the nicotine condition ($p < 0.05$), while after the 45 minute interval there was some evidence ($p < 0.10$) that recall was better after nicotine than no nicotine. The slight superiority of the nicotine group shows that the decrement in performance, after trial 10, could not be due to an impairment of information input and storage by nicotine and there could even have been an improvement of one of these processes. From the earlier discussion we can hypothesise that this effect could have been due to more efficient input of information after nicotine, and the impairment after trial 10 due to a change of state. The difficulty of interpreting the effects of nicotine in this study,

1002973476

and in the last one is that learning and recall are occurring over a 20 minute period while plasma and brain levels of nicotine fall by a half.

In a third study, relating nicotine and recognition memory, Andersson (1975 b) tested smokers on recognition of previously presented numbers. A set of the numbers 1-25 were randomly presented to the subjects who were required to respond if they remembered that they had seen a number before. Three sets of numbers were given so that the task became more complex as the test proceeded. There was a high nicotine cigarette (2.3 mg), a low nicotine cigarette (0.37 mg) and a no smoking condition. Heart rate increases indicated absorption of nicotine from the cigarettes. No statistically significant differences ($p < 0.1$) were obtained but on the first number, set recall was better in the no smoking condition than in the low nicotine condition, and recall was worst in the high nicotine condition. On the second and third number sets the order was reversed ie better recognition after smoking. These trends on the last two sets can be interpreted in terms of nicotine improving information processing by enabling the subjects to select the 'relevant' information (the digits of the present set) from the irrelevant (the digits presented in the previous set or sets).

The final study of Andersson (Andersson and Hockey, 1977) used a memory test that consisted of relevant and irrelevant information which enables this selectional interpretation to be examined further. A list of eight Swedish adjectives were presented, one at a time, in one of the four corners of a screen and the subjects were told that they would have to write down the words in presentation order ie the words and their order were relevant and by implication location was irrelevant. Two groups of smokers, deprived of cigarettes for 12 hours, received either a high nicotine cigarette (2.3 mg) or remained deprived. There were no differences between the nicotine and no nicotine groups for percentage of words that were recalled in the correct order, or for the percentage of words that were recalled correctly regardless of word order. This finding contradicts Andersson's previous evidence on recall. The most interesting

1002973477

finding was the decreased amount of irrelevant information recalled with nicotine; positions on the screen were recalled significantly less well with a group recall score of 30.2 per cent, which is only just above the chance level of 25 per cent. In a second test, in which subjects were required to remember words, word order and screen position, the groups did not differ significantly in their recall although there was a trend for location to be recalled better after nicotine (62.2 per cent) than when deprived (55.3 per cent). These data on recall also contradict the previous findings. This study suggests that nicotine can enable more limited and selective processing of information but it should be noted that the effect only occurs when the information is thought by the subjects to be incidental and not when the subjects were asked to remember it ie nicotine is not acting on a passive system.

In the earlier discussion the possibility of nicotine producing state dependent learning in human subjects was mentioned and numerous animal studies have given evidence of state dependency with cholinergic drugs (see review in Warburton, 1977). In a state dependent design one group of subjects learns after a drug dose while a second group learns after a placebo or no drug. For the recall test both groups are divided in two, one half of each group are tested with the drug of learning and half are switched to the other condition. If the recall scores are better for those groups which had the same drug state, then state dependent learning is said to have occurred. This state dependency hypothesis with nicotine has been investigated in several studies.

In the first published study (Houston, Schneider and Jarvik, 1978) 23 heavy smokers, deprived of cigarettes for three hours, read a list of words and were then given a free recall test prior to smoking in order to match the groups for learning ability. One group smoked a 1.5 mg nicotine cigarette and the other group smoked a non-nicotine cigarette. Smoking behaviour was controlled by asking the subjects to puff 12 times at thirty second intervals and to inhale and hold the smoke in their lungs for five seconds before exhaling. Although puff volume, puff duration and depth of inhalation were not controlled,

1002973478

the procedure would make it more likely that a relatively uniform amount of nicotine was absorbed by the group. Controlling the dose in this way makes the study pharmacologically sophisticated but it may be nonsensical from the point of view of the smokers, who would prefer to titrate for their own dose.

After this controlled smoking procedure, the subjects were given three successive lists with free recall tests after each one. The immediate recall scores showed that the nicotine group had significantly poorer recall than the placebo group although their pre-smoking scores were not different. These findings match those of Andersson and Post (1974) and Andersson (1975 a). Forty eight hours later, eight of the subjects from each condition returned for retesting and were sub-divided giving four groups of four subjects. They smoked either a nicotine or a non-nicotine cigarette as before, followed by another free recall test of all the lists. Once again the recall scores of the subjects, who smoked a nicotine cigarette at the time of learning, were significantly worse than those who smoked a non-nicotine cigarette which was not consistent with the findings of Andersson and Post (1974) and Andersson (1975 a). No evidence of state dependent learning was obtained, ie the group receiving a nicotine cigarette or a non-nicotine cigarette on both learning and recall did not have better scores than subjects who switched their cigarettes. However, with such small groups it is not surprising that no differences were found.

In contrast with the last study, two more studies have found positive evidence for state dependent learning with nicotine (Warburton, Wesnes and Shergold, 1982). The first experiment used the state dependent design to test nicotine's effect on recognition memory. Forty smokers, who were deprived of cigarettes for 10 hours, were given a 1.4 mg nicotine cigarette or allowed to relax immediately before serial presentation of a set of 30 Chinese radicals. After presentation, the subjects were allowed to read for one hour until the recognition recall test when they were divided into four groups - no smoking prior to learning and recall; no smoking prior to learning but a cigarette prior to recall; a cigarette prior to learning and recall; and a cigarette prior to learning but none prior to recall.

1002973479

Subjects who received nicotine prior to learning had significantly better recognition scores than the subjects who did not smoke in the first part of the experiment. There was no effect of nicotine on recall performance. A significant interaction term indicated that changing drug state interfered with recognition.

A more elaborate study examined the effect of a controlled dose of nicotine on short-term and long-term recall, within the framework of a state dependent design. Subjects, who were smokers deprived of cigarettes for ten hours, held a 1.5 mg alkaline nicotine tablet (pH 9) or a placebo tablet in their mouth for five minutes to allow nicotine absorption, tablets were then swallowed. Buccal and gastric absorption would be expected because of the alkaline tablet and this combination produces plasma levels of nicotine which remain stable for 30 mins (Russell and Wesnes, unpublished). After the tablet, the subjects listened to a list of 38 words and then did successive subtraction of seventeen from a larger number for one minute to prevent rehearsal. A free recall test was given for 10 minutes and then the subjects were allowed to leave the test room but were told that they would be called in 1 hour for a second, unspecified test. They were instructed not to smoke in this interval. During the hour they worked and were then recalled, given either nicotine or placebo tablets, depending on their group, and asked to recall as many of the words as they could in another 10 minutes free recall test.

The short term recall data revealed a very significant superiority of the nicotine group over the placebo group. Long term recall was also significantly better when subjects had taken nicotine prior to learning but not when taken prior to recall. The very significant interaction term again gave evidence for a state dependent effect of nicotine and showed that nicotine was facilitating the input of information to storage but had no direct effect on storage or retrieval. These findings are consistent with previous results which showed that nicotine facilitated information processing. However, the state dependency effect, for which there was some evidence in the studies of Andersson and Post (1974) and Andersson (1975 a), resulted in a poorer recall when subjects either learning with nicotine but recalled without nicotine or vice versa. In view of the previous discussion of

1002973480

nicotine's effects on information processing, a state dependent effect is not surprising because of the differences in the selection and processing of information due to nicotine increasing electrocortical arousal. A large body of literature has demonstrated that recall is better when the learning and recall situations are identical.

In conclusion, these studies show that in some circumstances nicotine can enhance the storage of information, probably because of more efficient input of information, but recall may be less efficient if the person is tested without nicotine. For habitual smokers this impairment would only be likely if they were deprived of cigarettes. It should be emphasised once again that this conclusion agrees with animal studies of learning with nicotine and with studies of cholinergic drugs and learning in general.

e. Motor Output

There is no evidence of gross changes in motor output after smoking doses of nicotine or nicotine tablets and the only change is a reliable increase in hand tremor after smoking (Larson et al, 1950). Although nicotine does act directly on neuromuscular junctions, (see sub-section IV B1) the tremor seems to be due to an effect on the central nervous system as well, perhaps at the level of the motor regions of the mesencephalic reticular formation. This fine tremor seems to have no practical significance except that it can be used as a marker for nicotine absorption.

f. Conclusions

Smokers report that they smoke to help them think and concentrate and the experimental evidence supports this rationale. Smoking and nicotine produce better selection of information from the environment and faster processing of that information which is reflected in improved attention and learning. There is some evidence that the improved learning by nicotine does not always transfer completely to the deprived condition and recall is partially impaired. This change probably has little significance for the habitual smoker who maintains plasma nicotine levels above some minimum level. The

1002973481

changes in sensory thresholds and hand tremor are inconsequential for most smokers.

2. Mood States

A large number of studies relating nicotine and mood have been carried out and so this review will be illustrative rather than exhaustive. It will focus on the mood states rather than the method of investigation and will discuss whether smoking does have sedative effects on anxiety and anger as smokers claim. In most cases the experimental studies have provided no evidence of nicotine absorption from cigarettes, and therefore it is not usually possible to separate the sedative effects of nicotine from the calming effect of the smoking ritual of cigarette manipulation.

a. Anxiety

Evidence for a sedative action of smoking comes from questionnaire studies, stress studies, personality tests of smokers and non-smokers, smoking abstinence studies and situations affecting smoking behaviour.

In a smoking motives survey, McKennell (1970) asked smokers about their mood states which might tempt them to smoke a cigarette and factor analysed the answers to extract the major factors which would produce smoking. One of these factors was "nervous irritation" smoking which included "smokes when anxious or worried" and "smokes when nervous" and also "smokes when angry". When the number of cigarettes smoked was controlled, female smokers exceeded the men for "nervous irritation" smoking. A factor analysis of smoking situations by Frith (1971) found a similar factor which he called high arousal smoking. High arousal smokers had a strong desire for a cigarette in stressful situations (eg an important interview) and women were more likely than men to smoke in these situations. Using a Smoking Motives Questionnaire, Russell et al (1974) and Warburton and Wesnes (1978) found that 93 per cent of smokers who attended a smoking clinic, 74 per cent of non-clinic smokers and 88 per cent of students said that they smoked when worried. Altogether, this evidence shows that smokers believe that smoking is beneficial to them when they are anxious.

1002973482

01.

The bulk of the experimental evidence for smoking helping in stress situations has come from Stanley Schachter's laboratory. Nesbitt (1973) tested smokers, who used 20 or more cigarettes a day, and non-smokers on a shock tolerance test, on the assumption that it provided a measure of anxiety. Both groups were asked to smoke a 1.6 mg or 0.3 mg nicotine cigarette or puff on an unlighted cigarette. It was found that smokers who were smoking could take up to 2,450 microamps more after smoking and this effect was dose dependent. On the other hand, the non-smokers tolerated more shock in the no smoking condition but slightly less after the high nicotine cigarette. Assuming that shock tolerance is a measure of anxiety the simple explanation that smoking reduces anxiety does not fit this data because smokers who were only allowed to puff an unlighted cigarette tolerated less shock than non-smokers in the same condition. The latter finding suggests that nicotine from the smoke is more important than the smoking ritual in the effect on anxiety, but also that absence of nicotine in smokers results in more anxiety than for non-smokers. This finding could mean either that a nicotine deficit results in abstinence symptoms due to physiological dependence on nicotine or that smokers are constitutionally more anxious.

The latter possibility can be examined from personality studies of smokers. One influential theory of individual differences in behaviour is based on the dichotomy between extraversion and introversion and between neuroticism and stability and can be measured by a questionnaire such as the Eysenck Personality Inventory (Eysenck and Eysenck, 1964). People having high scores on neuroticism displays labile, emotional behaviour and are anxious, irritable, moody, restless, excitable and changeable. In contrast, stable people are calm and even tempered. There is less consistency in the evidence for a relationship between smoking and neuroticism, and Eysenck's studies of 6,000 men gave no evidence for a significant correlation (Eysenck *et al*, 1960; Eysenck, 1963 a). Rae's (1975) survey of 253 female students revealed no differences in the degree of neuroticism between non-smokers, ex-smokers, light smokers or medium smokers, but there were very few heavy smokers (over 15 per day) in his college sample. However, at least seven studies have suggested a positive relationship of smoking with neuroticism and this association is particularly strong for

1002973483

women smokers (Meares, et al, 1971; Waters, 1971; Dunnell and Cartwright, 1972).

In research at Reading University (Warburton, Wesnes and Revell, 1982) a questionnaire was given to 250 student male and female smokers to obtain information about the number of cigarettes smoked a day, the number of years that the individual had been smoking and the specific brands smoked. All the smokers completed the Eysenck Personality Inventory as well. Analysis of the data on number smoked per day and level of neuroticism of the whole group disclosed no association of smoke with neuroticism. However, for both sexes the distribution of number of cigarettes per day was bimodal with a separation around 15 cigarettes per day, in agreement with the results of a survey by Schachter (1978). This distribution suggests that there are two populations of smokers, light smokers and heavy smokers, as far as number of cigarettes smoked is concerned. The personality and smoking data were analysed separately in four groups, defined by sex and whether they were heavy or light smokers, so that the correlations within each of the four groups could reveal associations which may exist between smoking and neuroticism level. A positive correlation was found between the number smoked per day and the degree of neuroticism (ie the more neurotic smokers in each group smoked more cigarettes per day), even though the mean neuroticism scores of light and heavy smokers did not differ. Thus neuroticism was not related to whether a smoker was either a heavy smoker or light smoker, but within each sub-population, the number that he or she smoked per day was related to the degree of the individual's neuroticism. The heavy smokers were more extraverted than the light smokers and within each of these groups the male smokers were less extraverted than the females. In brief, light or heavy smoking was associated with extraversion, but within these two sub-populations, the number smoked per day was associated with neuroticism.

From these data one can speculate that the constitutional factors, which result in extraverted behaviour, determine whether a person becomes a light or heavy smoker whereas the factors that underlie neuroticism are not associated with heavy or light smoking, but influence the number smoked per day if an individual is a light or heavy smoker.

1002973484

Another interesting relationship emerged when correlations between personality and cigarette strength were considered. While extraversion scores were not correlated with the strength of cigarettes smoked, neuroticism scores were positively correlated for women, uncorrelated for male, light smokers and negatively correlated for male, heavy smokers so that the more neurotic females smoked higher delivery cigarettes.

Of course, these correlations were based on the machine-estimated yields of the cigarettes smoked and do not tell us how much nicotine was actually absorbed by the smoker. Self-report of depth of inhalation also varied among the personality groups. Deep inhalers had a higher mean neuroticism score than slight inhalers whose neuroticism scores were the same as non-smokers which suggests that smokers who score high on neuroticism absorb more nicotine.

In summary, we can safely conclude that the strength of cigarettes that are purchased by women smokers is related to their degree of neuroticism, and from the whole body of survey data that women buy cigarettes in order to help them cope with neuroticism.

Although this evidence is persuasive, Schachter might still argue that repeated exposure to nicotine had caused anxiety and a higher neuroticism score. Evidence against this argument is the lack of an overall correlation between number smoked and neuroticism. A second piece of evidence comes from a crucial study done by Cherry and Kiernan (1976; 1978) which has followed a cohort of 2,853 young people for 25 years. When they were 16 years old the subjects completed the Maudesley Personality Inventory before most of them had begun to smoke. At 20 years and 25 years of age they completed a smoking habits questionnaire and it was found that the cigarette smokers, as a group, were more extraverted and neurotic as we would have expected and those teenagers who smoked regularly before 16 years of age were more neurotic and more extraverted than smokers who did not smoke before they were 16 years old. A statistical analysis revealed that the two personality dimensions are independent and additive in their effect on the likelihood of becoming a habitual smoker and indicated that the constitution factors underlying anxiety produce smoking and not the other way round.

1002973485

As was pointed out earlier (Section III D) smokers can titrate for nicotine by varying the number of cigarettes smoked, their patterns of puffing and the amount of smoke inhaled. From these findings it can be predicted that smokers should titrate for nicotine depending on the situational demands, if they are smoking for nicotine to reduce anxiety. Schachter (1976) described two studies in which he studied stress and the number of cigarettes that were smoked. The subjects were tested with electric shock ostensibly to determine their tactile sensitivity. In the low stress condition smokers only received a low level of current to produce a tingle while the high stress group were occasionally given a painful shock. Schachter counted the number of cigarettes smoked between tests in the laboratory and found that the subjects smoked more cigarettes in the interval after the high stress condition than after the low stress condition ie when they were anxiously anticipating the next test series. Unfortunately, he did not collect any information about smoke generation and smoke manipulation.

In a recent study (Warburton et al, 1982) 48 first year undergraduates filled in a detailed diary on their smoking habits during a first year examination period and again 6 weeks later, after the examination results had come out. This design enabled us to compare the smoking behaviour of students in a high stress and a low stress period of their lives and find how people adjust their cigarette intake according to the situation. From the cigarette totals for the afternoons and evenings it was obvious that subjects smoked significantly more cigarettes at all times during the examination period than six weeks later. The mean number of cigarettes smoked during the morning before an afternoon examination was 80 per cent above the average number for mornings during the non-examination period and had increased by 29 per cent over the mean morning consumption for the examination period as a whole. The mean number of cigarettes smoked in an evening before an examination was higher than the mean for evenings in the non-examination period.

Subjects gave a subjective evaluation of their degree of inhalation and these reports followed exactly the same pattern as the data for number of cigarettes smoked ie, highly significant increases in degree

1002973486

of inhalation during the examinations with respect to the post-examination period. There was greater inhalation during the morning before an afternoon examination compared with the mean for mornings of the non-examination period. The degree of inhalation for the evening before a morning examination was significantly higher than the mean for an evening prior to a free day. Similarly, a comparison of the evening before a free day, within the examination period, with the mean for evenings, in the non-examination period, gave significant differences for degree of inhalation. Once again the individual data are highly consistent.

Thus the undergraduate students who took part in this study increased the number of cigarettes that they smoked quite dramatically when faced with examinations and the concomitant stress. They also felt that they were inhaling more than during the non-examination period. It can be assumed that the two questionnaires were fairly independent since the first was completed and returned six weeks before the second.

Some experimental evidence for titration by puffing was found by Ashton and Watson (1970) with subjects smoking in a driving simulation task. Subjects were tested in an easy driving task, a stressful driving task and at rest. In all situations they found that subjects puffed more frequently at the medium nicotine cigarettes (1.0 mg of nicotine on machine-estimated delivery) than the high nicotine cigarettes (2.1 mg nicotine on machine-estimated delivery), and butt analyses revealed that they took into their mouths nearly the same amount of nicotine from each brand. Interestingly, subjects generated more nicotine from the cigarettes during the more stressful test than the easier test, although the differences were not statistically significant, which suggests that individual smokers titrate the nicotine delivery from the cigarette according to the situation.

The Reading University research programme has examined the situation \times individual \times smoking interaction by studying the amount of nicotine taken by subjects in the vigilance test mentioned earlier (Warburton and Wesnes, 1978). Correlations were made between the neuroticism scores and the butt nicotine level from the test cigarettes. There was some evidence that the more neurotic subjects puffed harder than the more stable subjects on the first cigarette of

1002973487

the test period. However, a more interesting association was found between neuroticism and the change in smoking pattern over the session. A positive correlation was found between neuroticism and the difference in smoke generation between the first and last cigarette for both the low nicotine cigarette and the high nicotine cigarette, indicating that the more neurotic subjects smoke more intensely at the beginning of the session than at the end of the test. This result provides further evidence that one aspect of smoking behaviour is the outcome of the interaction of the situation and the individual.

Anxiety arises in situations of uncertainty when a person is subjected to an unpredictable pattern of stimuli or is faced with uncertainty about which response to choose, or both (Warburton, 1979) and this effect will be greater in more neurotic subjects in our test situation. Consequently, it can be argued that the more neurotic subjects found the test situation particularly stressful, and so they smoked more intensely because they have a greater need for nicotine in order to cope with the experimental test. This result is consistent with the trend in the data of Ashton and Watson (1970) that stress increased smoking intensity.

This research strongly suggests that smoking behaviour changes in stressful situations; smokers use more cigarettes, smoke them more intensely and inhale the smoke more deeply. The more neurotic subjects (those who are more anxious and susceptible to stress) show the most marked effects. The interesting question is: Does smoking help to cope with stress and improve behavioural efficiency? Accordingly we have analysed performance increments as a function of neuroticism and found that there was a direct association between the degree of neuroticism and the amount of performance improvement (Warburton and Wesnes, 1978). The latter association is consistent with data obtained by Kucek (1975) in an experiment where subjects were tested under conditions of information overload in which they were required to track a target and do mental arithmetic. A comparison of neurotic smokers allowed to smoke and neurotic smokers not smoking showed that smoking had a beneficial effect on the performance of neurotic subjects allowed to smoke.

1002973486

Nicotine is the most likely constituent of cigarettes for producing this improvement in performance, and in another vigilance study we tested nicotine tablets containing doses of nicotine in the range of those estimated as entering the smokers mouth in the previous study. For both females and males the improvement scores were directly correlated with neuroticism (Warburton and Wesnes, 1978). This significant association with neuroticism gives strong evidence for the hypothesis that nicotine is the sedative ingredient of cigarette smoke which is beneficial for performance, especially for the more neurotic subjects.

Inferences about the properties of a drug can often be made from the symptoms that occur when medication is terminated; for example the function of insulin for a diabetic person can be inferred from the symptom that occurs when injections are discontinued. Studies of withdrawal symptoms that follow cessation of smoking show that one of the major symptoms of cigarette withdrawal is anxiety (Nesbitt, 1972; Shiffman and Jarvik, 1976). It is more likely to occur among women because in this group there is a greater proportion of neurotic smokers (Guilford, 1966; Shiffman, 1979 b). Anxiety is also given as one of the major causes of relapse, especially among women (Shiffman, 1979 b). An analysis of the situations which resulted in a return to smoking was made by Marlatt (1979) and Shiffman (1971 a). Retrospective reports indicated that 80 per cent of these situations fell into three categories: coping with anxiety and other negative emotional states (43%), social pressure (25%) and coping with social stress (12%). Few of Marlatt's and Shiffman's relapsed smokers reported that physical withdrawal symptoms triggered the relapse which argues against the hypothesis that smokers carry on smoking because of physical dependence. In the Shiffman (1979 a) study, two thirds of the subjects were under stress at the time of relapse and anxiety was particularly common among ex-smokers who relapsed at work, which suggests that work-related anxiety was a contributory factor. Neurotics are more anxiety-prone and so it is not surprising that this group find it difficult to stop smoking or relapse if they do abstain (Cherry and Kiernan, 1978). These data on smoking to cope with stress fit neatly with studies which suggest that deprived smokers, as a group, are more likely to respond with anxiety in situations in which they are stressed. (Frankenhaeuser, et al, 1971; Myrsten, et al, 1972; Schachter, 1978).

1002973489

A large epidemiological study of British doctors has given some evidence which may indicate there are adverse consequences of smoking cessation (Lee, 1979). As a group, doctors have reduced their cigarette smoking over 20 years, and there has been some of the expected improvement in mortality rate from the so-called "smoke-related" diseases, but the overall death rate did not fall as much as one might have predicted from other groups of similar socioeconomic status. The reason for this discrepancy is that mortality from other causes has increased. In particular, stress-related deaths have increased relative to other professions in the equivalent social class, and more doctors have died from accidents, poisonings, suicide, and cirrhosis of the liver. Lee concludes that "the relative worsening in mortality from stress-related diseases may have been due partly to a possible adverse effect of giving up smoking if smoking had acted to reduce stress" (p 1538). This conclusion must be treated with caution because it is always very hazardous to argue from correlation to causality but, nevertheless, it is consistent with the previously cited research on smoking and stress.

In summary, a large body of evidence indicates that smokers smoke to reduce anxiety and smoke more and presumably take more nicotine when under stress. Subjects who are more prone to anxiety, ie scoring high on the neuroticism scale, smoke more intensely. Some experiments show that nicotine helps them cope with the situation better. Ex-smokers report that anxiety is one of the major problems of cessation and there is evidence that stress can lead to relapse. Those smokers who do abstain seem to be more prone to stress-related disorders and the full benefits of stopping smoking in terms of decreased mortality may not be achieved.

b. Anger

Another item that made up the "nervous irritation" factor of smoking in the McKennell (1970) questionnaire was anger. Thomas (1973) reported that on her "habits of nervous tension" questionnaire cigarette smokers and former smokers had higher levels of irritability and anger in comparison with lifetime non-smokers. When

1002973490

the smokers were divided into light (less than 20 a day) and heavy groups, the heavy smokers showed greater anger under stress than the light smokers. In two studies of smokers at a stop-smoking clinic and non-clinic smokers (Russell et al, 1974) and student smokers (Warburton and Wesnes, 1978), smoking when angry was one of the "top 10" reasons given for smoking by smokers attending a stop smoking clinic (83 per cent), non-clinic smokers (47 per cent) and student smokers (65 per cent). It appears from this consistency that a feeling of anger is a motive for smoking in some people.

Experimental studies of anger are difficult to conduct and no satisfactory experiments on nicotine and anger in humans have been done. Schachter (1978) reports a study by Perlick which compared irritability in groups of "unrestrained" and "restrained" smokers: the latter were trying to cut down their smoking and smoked less of the cigarettes. Each group were then exposed to aircraft noise and asked to rate the annoyance caused by the noise, after smoking either a 1.3 mg nicotine cigarette, a 0.3 mg nicotine cigarette or not smoking. It was found that unrestrained smokers, when deprived or smoking the low nicotine cigarette, were more annoyed than when smoking the medium nicotine cigarette. However, unrestrained smokers, when smoking the medium nicotine cigarette, were no better than non-smokers. The restrained group were just as irritated in all three conditions as the deprived or low nicotine, unrestrained smokers. There are at least two explanations for these results; either irritability is an abstinence symptom which is the consequence of nicotine dependence, or smokers are constitutionally more irritable and nicotine from smoking helps to reduce this feeling.

Studies of abstinence have shown hostility and aggressive behaviour increase markedly during abstinence (Mausner, 1980; Schachter and Rand, 1974; Shiffman and Jarvik, 1976). Anger is commonly reported as a factor triggering relapse among ex-smokers, and these relapses occurred in the absence of smoking-related cues such as "people around were smoking". (Shiffman, 1979 a). Clearly, the smoker who is deprived of nicotine is less calm. Evidence from a study by Thomas (1973), which showed similar scores for anger when stressed for smokers and ex-smokers, suggests that smokers are constitutionally more angry and irritable.

1002973491

In summary, smoking, and by inference nicotine, seems to have sedative effects for anger as well as anxiety.

3. Conclusion

These findings of enhanced psychological efficiency after nicotine are interesting from a psychopharmacological point of view because, although many drugs impair performance, it has proved difficult to find drugs which produce real improvements or even sustain performance in healthy, well-motivated subjects. The finding that nicotine can also act as a sedative makes the enhancement even more interesting because drugs with anti-anxiety action usually impair performance at effective doses. Thus nicotine is a unique substance because it combines both performance enhancement with anti-anxiety and anti-anger action.

While these findings alone are interesting, they assume even greater significance when they are considered in the light of the smoker's precise personal control over nicotine intake. The data in the preceding sections can be combined to argue that cigarette smoking can be regarded as self medication for certain groups. Studies of self medication suggest that people use those classes of drug which fulfil their own individual needs (Warburton, 1978) and the research presented here shows that people titrate nicotine to obtain a specific dose to fit their needs. Depending on the situation, smokers will adjust their smoking behaviour in terms of the number of cigarettes smoked, smoke generation and amount of smoke inhaled to control the nicotine levels reaching their brain and in this way their psychological state. Deprivation of cigarettes results in marked abstinence symptoms which are manifested as less efficient functions in certain situations, and so relapse is likely to occur in these contexts.

Consequently, the behaviour of a smoker is the outcome of a complex set of interactions. It is obviously determined, not only by the characteristics of the situation, but also by the personality of the individual. The personality characteristics will determine the way in which the individual selects and interprets information within the situation ie there is an interaction going on between individual factors

1002973492

and situational factors. If it is assumed that individual differences have a constitutional basis (ie differences in the neurochemical pathways in the brain) then another complex interaction occurs when a drug is given to a person. Drugs do not affect human performance directly, but they produce changes in behaviour as a consequence of their interaction with endogenous chemicals within the body. Changes in neurochemical activity in the brain alter the way in which a person interacts with his environment and so performance not only reflects the nature of the drug but also the biochemical state of the person at that moment.

In sections (a) and (b) we have discussed the "stimulation" (low arousal) smoker and the "sedative" (high arousal) smoker as if they were homogeneous groups who self-medicated in the same way all the time. However, there must be differences in smoking behaviour as a function of the intensity of the individual-situation interaction, its duration and more probably its density (the product of intensity and duration). For example, a stimulation smoker may need less nicotine in brief, slightly boring tasks than a prolonged tedious situation, but conceivably the same smoking behaviour could occur during a brief, very boring, experience and a long, but moderately interesting task. In other cases smoking may not even be initiated until the intensity, duration or density of the interaction is at a critical level. Clearly, lighting a cigarette and the pattern of smoking behaviour depends on the individual-situation interaction.

An important extension of these concepts can be made on the basis of the observation that some smokers smoke in anticipation of a future need, before the situation has occurred or the critical stress level has been reached, and they are still coping. Here the smoking behaviour is very clearly a response to the individual's interpretation of the situation, his expectations about what may occur, rather than the objective characteristics of the situation. Smokers have learned that self-medication by smoking will enable them to function more efficiently on some tasks and will help them avoid the undesired consequences of other situations and so anticipatory smoking can be seen as a rational coping strategy on the basis of their past experience.

1002973493

Advocates of abstinence and the operators of stop smoking clinics have disregarded this information. They have focused on the smoke-related diseases and not considered the benefits of smoking. The smoking habit must be considered from the point of view of the smoker. If he smokes and absorbs nicotine he will function more efficiently now, but risks impaired health in the future. If he abstains he loses the benefit of nicotine and may have better health in the future. It is not surprising that many smokers choose to continue smoking, that abstaining smokers relapse, and stop smoking programmes have a conspicuous lack of success. In the next section we will consider nicotine in the context of some other substances which have been used by people to control their mood or to help them perform better.

1002973494

V. NICOTINE USE IN PERSPECTIVE

1. Introduction

When evaluating nicotine use and the smoking habit it is important to compare nicotine with other substances which are habitually used and compounds which produce similar effects. Comparisons with reference substances are an essential part of the assessment of any therapeutic agent so that the relative costs and benefits can be estimated and decisions made about the agent's usefulness. In the case of nicotine, which has stimulant and sedative properties, the selected reference agents are the psychostimulants, amphetamine and caffeine, and the sedatives, diazepam (Valium) and alcohol. In addition we have also included marijuana (active ingredient is Δ^9 -tetrahydrocannabinol or THC), which is inhaled for its pleasurable effects.

The comparison takes the form of an analysis of both the pharmacokinetic and pharmacodynamic features of these substances which could constitute risk to the user. The important pharmacokinetic features are absorption, user control of dose, duration of action, side effects that would impair normal functioning (acute toxicity), chronic toxicity in terms of damage to brain and body, and abuse potential.

2. Absorption

As we have seen, nicotine inhaled into the lungs, is readily absorbed and travels from the pulmonary vein to the brain within ten seconds to reach peak concentration immediately after the last puff of the cigarette, ie about seven minutes after lighting up (see Section II). An oral dose of alcohol must travel through the stomach, where some absorption may occur depending on the stomach contents, to the major site of rapid absorption in the small intestine. Gastric emptying time and thus the onset of absorption results in a variable rate of uptake so that peak concentrations of alcohol in plasma are reached between 40 minutes and 120 minutes (Lemberger and Rubin, 1976). Diazepam is also absorbed from the

1002973495

gastrointestinal tract and several hours are needed to achieve peak blood and brain levels (Kornetsky, 1976). Amphetamine and caffeine are absorbed from the stomach and peak concentrations in plasma and brain are reached about 30 minutes after an oral dose of caffeine (Marks and Kelly, 1973) and between one and three hours after an oral dose of amphetamine (Beckett, 1970). Amphetamine is also taken intravenously and peak doses in the brain can be achieved within five minutes (Lemberger and Rubin, 1976). The absorption of THC into the bloodstream is rapid when inhaled and it passes rapidly to the brain, but uptake into the brain is slow so that only one per cent appears in rat brain at 60 minutes (Lemberger and Rubin, 1976). Obviously, nicotine reaches potential active sites in the brain very quickly in comparison with these reference substances.

Absorption time is significant for personal control of effect and prevention of over-dosing; a fast absorption time enables the user to adjust his dose to his requirements and so control the magnitude of effect. An ideal agent for self-medication would enable the person to fit the dose to his needs. Smokers have puff by puff control with brain effects occurring within 10 seconds while a drinker must choose an "appropriate" dose for effects in an hour or so. Thus in terms of personal control the experienced smoker has precise control over nicotine's psychoactive effects whereas most drinkers have very haphazard control. Precision of control is also particularly important when considering toxicity because the risk of exceeding the optimal dose is minimised.

3. Duration of Action

A second aspect of pharmacokinetics, which is also related to personal control of a person's psychological state, is duration of action. Psychological needs vary and most people want coping techniques for specific occasions rather than for chronic states. Thus stimulation may be needed for an arduous task but not some hours later at bedtime; anxiety reduction is required for a 10 minutes interview with a director but not for interacting with colleagues.

1002973496

Nicotine has a half-life of only 20 minutes and is cleared from the body in about 40 minutes (see Section II). In comparison, alcohol (Beckett, 1970) and caffeine (Marks and Kelly, 1973) have half-lives in the range of 3-4 hours and both may remain in the body for 8-12 hours (Gilbert, 1976). Although these values are several orders of magnitude more than for nicotine they are insignificant in comparison with the 20-50 hours for the elimination half-life of diazepam (Breimer, 1979) and 56 hours for THC (Lemberger and Rubin, 1976). In addition, diazepam and THC have active metabolites that further prolong their action while cotinine the major metabolite of nicotine seems to be virtually inactive.

Clearly nicotine fits the pharmacokinetic specifications of a compound which a person can use to self medicate and exert fine control over his psychological state on an hour by hour basis.

4. Specificity of Action

One of the important pharmacodynamic criteria for a therapeutically useful agent is that it is relatively specific in its mode of action. Ideally it should be a "magic bullet" that moves specifically to the target site and exerts its action at no other loci. Much more common among psychoactive substances are those which act on several biochemical systems even at low doses. The acetylcholine, dopamine, noradrenalin and serotonin systems are all modified directly by alcohol (Israel and Mardones, 1971), caffeine (Gilbert, 1976) diazepam (Warburton, 1975) and THC (Harris, 1978). In contrast, amphetamine which only acts on the dopamine and noradrenalin systems, is relatively specific (Lemberger and Rubin, 1976). From the balance of evidence available, smoking doses of nicotine only act directly on some of the acetylcholine systems in the body (the so called "nicotinic" pathways). Nicotine's molecular structure is similar enough to the acetylcholine molecule to mimic it and so produce normal changes in these pathways. This specificity of action decreases the likelihood that a drug will produce unwanted "side effects". This aspect will be discussed in more detail in the next section on toxicity.

1002973497

5. Toxicity

Almost all substances have toxic effects if taken in large doses for a sufficiently long period of time. In this section we will consider the acute, unwanted effects of the reference compounds and the chronic consequences of normally-used doses taken over a long period of time.

Although amphetamine can improve performance in laboratory tests there is evidence that the drug also distorts judgement so that the subject believes that the improvement is greater than it is. As well as distorting judgement, amphetamine acts as a sleep and appetite suppressant, and chronic use of the drug invariably leads to loss of weight due to reduced food intake. Repeated use of the drug results in tolerance so that higher and higher doses are needed to obtain the stimulant effects. Frequent small doses of amphetamines produce psychotic episodes in normal subjects (Kornetsky, 1976) and repeated use of high doses result in severe psychosis. Obviously amphetamine use is fraught with risks.

Caffeine is a much less harmful stimulant than amphetamine but is not without toxic effects. Gilbert (1976) reviewed the literature and concluded that there is considerable risk to the health of an average adult from the consumption of over 600 mg of caffeine a day (about eight cups of coffee). Such an adult will be more likely to experience headaches, insomnia, anxiety and depression on waking. Repeated use increases the likelihood of myocardial infarction, stomach ulcers, duodenal ulcers, and carcinoma of the kidneys and urinary tract. Recently it has been implicated with pancreatic cancer (MacMahon et al, 1981). Clearly, caffeine is not an entirely harmless compound although it is a much safer, but less potent, psychostimulant than amphetamine.

In view of alcohol's non-specific biochemical action it is not surprising that moderate doses of alcohol have a variety of acute unwanted consequences. It has a general, non-selective effect on all neural systems which lead to impairment of all types of performance eg thought, memory, concentration, fine movement, and motor control. As a consequence, anxiolytic doses are incompatible with most types of work. Moderate drinking probably cause very little chronic toxicity in terms of psychological and physiological functioning but repeated use of the drug

1002973498

results in larger and larger doses being required for anti-anxiety effects. Long term use of larger amounts leads to deterioration of the brain, liver and other organs (Wallgren and Barry, 1971).

The most common side effects of diazepam is drowsiness and impairment of concentration. These acute toxic effects are small but not insignificant in a fit, unfatigued person who has taken no alcohol, but are hazardous in a tired person or someone who has taken even a small amount of alcohol. It should also be remembered that the drug persists in the body for days and so the alcohol interaction could occur long after taking a dose. The evidence for chronic toxicity with diazepam is small and, although some tolerance develops, there is not the dramatic escalation of doses that can occur with alcohol (Marks, 1978). From the point of view of acute and chronic toxicity diazepam is a much safer anxiolytic than alcohol.

Alcohol use is often compared unfavourably with marijuana use, but the problem with this toxicity comparison is that we know so little about Δ^9 -tetrahydrocannabinol (THC) and its active metabolites. Performance testing has revealed that cognitive ability and reaction time are impaired and, not surprisingly, driving skills (see review in Warburton, 1975 and Kornetsky, 1976). There is no evidence that repeated casual use has adverse consequences but an amotivational syndrome after frequent use of marijuana has been reported (Warburton, 1975; Kornetsky, 1976).

A typical list of the toxic effects of nicotine includes sweating, tremor, nausea, vomiting, abdominal pain, diarrhoea, palpitation, fatigue and headache (Cohen and Roe, 1981) but of these symptoms only tremor occurs in experienced smokers which suggests that either tolerance to these effects has occurred or the smoker titrates his dose to avoid the unwanted adverse effects. There is no evidence of intellectual impairment during use and, on the contrary, nicotine improves psychological performance (see Section IV D). This benign action seems to be due to the similarity between nicotine and acetylcholine, so that nicotine acts in a natural way on neurones and only produces changes in the brain which occur normally in states of alertness. As a consequence of its similarity to acetylcholine, tolerance to its action on electrocortical arousal does not occur (Murphree, 1979). This lack of tolerance is not surprising because neurones cannot become tolerant to their own chemicals otherwise they would cease to

1002973499

function. Without tolerance to the desired effects, smokers do not have to keep on increasing the dose to achieve the desired amounts of sedation or stimulation. Evidence for chronic toxicity due to nicotine alone, rather than cigarette smoke, is sparse and there is little convincing evidence of intellectual impairment even after a lifetime of use. Chronic nicotine use has sometimes been linked to gastrointestinal disturbance and cardiovascular disorders but no studies have controlled for caffeine and alcohol consumption which are associated with both sorts of disorder. Thus, nicotine, in smoking doses, has little known toxicity itself and the hazard to the smoker is in the other smoke constituents.

In summary, the ranking of compounds for toxicity, considering the doses which are in general use, would be alcohol (severe toxicity with potentially severe chronic toxicity), amphetamine (minor acute toxicity but severe chronic toxicity), marijuana (acute toxicity and perhaps minor chronic toxicity) caffeine (minor acute toxicity and moderate chronic toxicity), diazepam (minor acute toxicity and little chronic toxicity), and nicotine (no acute toxicity in smoking doses and little known chronic toxicity).

6. Abuse Potential

Use of any substance can only be evaluated with respect to the situation of use, the manner of use as well as the consequences of use (Balter, 1974). Normal use can be defined as consumption for an innocuous or constructive purpose in moderate amounts and in the appropriate context in terms of place and culture. Abuse focuses on adverse consequences of use in terms of physiological or psychological effects. The consequences of abuse are organ damage and impairment of social and personal functioning. Indirectly, abuse refers to the manner of use by the person (pattern and amount taken). The problem of abuse is in the person's interaction with the compound and is not a fault of the compound itself. However, some substances are more likely to lead to abuse than others and this aspect is referred to as abuse potential. The abuse potential of a substance can be defined in terms of its intrinsic attractiveness (Balter, 1974), the number of users (Balter, 1974) and the number of users who become abusers of the substances (Balter, 1974).

1002973500

7. Intrinsic Attractiveness

Attractiveness refers to the extent to which most users find the immediate effect of a substance intrinsically pleasing. Intrinsic attractiveness is independent of cultural factors and can be assessed from laboratory studies with animals. In the laboratory, animals learn to lever press in order to self-administer some drugs and intrinsic attractiveness is assessed from the ease of learning and the regularity of pressing. While animals will rapidly self-administer amphetamines showing the high intrinsic attractiveness of this compound, animals self-administer alcohol and THC to a much lesser extent showing that these compounds have less intrinsic attractiveness. There is no evidence that animals will self-administer diazepam or caffeine at all, indicating negligible intrinsic attractiveness. Attempts to train animals to self inject nicotine or "to smoke" have been rather unsuccessful which suggests very low intrinsic attractiveness (Kumar, 1979).

These laboratory studies fit with human comparisons of the compounds which indicate that intravenous amphetamine produces pleasure like a "pharmacogenic" orgasm, alcohol and THC produce moderate euphoria, while caffeine produces stimulation but no euphoria and diazepam is pleasurably relaxing but does not produce euphoria. Nicotine can be either mildly stimulating or pleasurably relaxing depending on the situation, but is not a euphoriant. The production of euphoria seems to be essential for high intrinsic attractiveness and for strong habit formation.

The strength of habit formation for non-durable commodities has been estimated by economists by time series analyses of demand (see Houthakker and Taylor, 1966). In their equations they include a parameters for the psychological "stock" of consumption habits because for some commodities, demand does not adjust to changes in prices or income. Current consumption is positively influenced by use of the commodity in the more or less recent past indicating some degree of habit formation. If a smoker has built up a psychological "stock" of smoking habits, then the number of cigarettes that have been smoked in the past will influence current consumption. If we consider the same population (eg United States 1929-1960, before any of the health campaigns), then we can compare the psychological "stock" for

1002973501

tobacco consumption with that for alcohol consumption by using the estimates for this parameter in the demand equations. These estimates show that tobacco use was subject to some habit formation (positive parameter value of 0.1743) but it was much smaller than psychological "stock" for alcohol consumption (parameter value of 1.0869). This conclusion would be consistent with the information on relative intrinsic attractiveness of alcohol and nicotine.

In summary, amphetamine produces a very pleasing effect on most people. Alcohol and THC are moderately attractive while caffeine, nicotine and diazepam have little intrinsic attractiveness.

8. Percentage of Abusers

An abuser is a person who is consuming a drug in sufficient quantities to produce damage to health. A comparison of the number of users and abusers is difficult because nicotine, caffeine and alcohol are readily available while amphetamine and diazepam are controlled and marijuana (THC) is illegal. However, the pattern of available evidence is consistent with the data on intrinsic attractiveness. When amphetamines were freely available on prescription in Britain, 10% of the population of Newcastle were receiving amphetamine prescriptions and 20% of the users were abusing the compound (Kiloh and Brandon, 1962). Alcohol and caffeine are socially acceptable substances which are consumed by over 95% of the population in most Western cultures and of these about 5-7% abuse alcohol (Kissin, 1972) and about 3% are caffeine abusers (Gilbert, 1976). It is estimated that 5-7% of THC users are abusers (Kissin, 1973). Abusers of diazepam are rare and current estimates would place the percentage at less than 1% (Marks, 1976). Strictly speaking, the number of abusers of nicotine is zero since few individuals take pure nicotine and nicotine itself is not known to contribute to the smoke-related disorders (Cohen and Roe, 1981).

Abuse potential has also been defined in terms of difficulty of stopping use. Of the reference substances, comparable data are only available on alcohol and smoking. Hunt and Bospalec (1974) compared the relapse rates for alcoholics and smokers with heroin (an agent with very high intrinsic attractiveness) and found that the relapse curves were very

1002973502

similar. This similarity has been used as evidence for the strong abuse potential of nicotine and for a common mechanism underlying use of all these substances. However, as Jaffe and Jarvik (1978) point out, while one may wonder what drives a heroin abuser to relapse in the face of the social disapproval, the physical hazards and legal risks of heroin use, it is surprising that relapse among ex-smokers is not universal given the multiple motives for smoking and the fact that a heavy smoker will experience the beneficial effects of stimulation or sedation from nicotine hundreds of times a year.

In summary, the overall rankings for abuse potential of the substances in terms of intrinsic attractiveness and number of users is amphetamine, alcohol, marijuana, caffeine with diazepam and nicotine having virtually zero abuse potential.

9. Conclusions

Nicotine, as used by the smoker, is a low risk substance in terms of acute and chronic toxicity and the smoke-related diseases can only be due to the other smoke constituents. Its rapid uptake into the brain allows smokers to control their psychological state at will so that they can obtain either stimulation or sedation to help them to cope with situations. Nicotine's specific action on the brain produces neural changes which are within normal limits and so nicotine acts in a normal way to produce stimulation and sedation. Nicotine is not like other so called "addictive" substances and has low abuse potential. The smoking habit is so strong because of the ability of nicotine to provide smokers with exquisite personal control over their psychological functioning. If future research could reduce those smoke constituents that produce toxicity then people, who need the benefits of nicotine, could obtain these without risk. Certainly no comparable, lower risk compounds are available at the moment.

1002973503

VI. CONCLUDING COMMENTS

Tobacco has been used in the Americas for three thousand years and its use has spread to nearly every culture in the world in the last five hundred years. Cigarette smokers puff a rod of burning tobacco and the majority of them inhale the smoke. As a consequence of smoke intake, a number of smoke constituents are absorbed and nicotine is the most active pharmacological ingredient of these compounds. Nicotine is absorbed very efficiently, enters the brain very quickly and a smoking dose is metabolised in 40 minutes which allows for brief duration of action. Smokers are sensitive to their plasma nicotine levels and they can control their intake of nicotine because of the rapidity of uptake and their perception of the moment to moment changes of nicotine level in their brain. Not only do smokers control nicotine by varying their cigarette consumption, but they control the strength of puffing to modify smoke generation, the amount of smoke retained for inhaling, and the degree of smoke inhalation for nicotine absorption. This control is more than avoidance of high toxic doses of nicotine but is an attempt to titrate for a specific nicotine dose by smoking high nicotine products less intensely and smoking low nicotine cigarettes more intensely.

The smoker's aim in titrating is obtaining an optimal dose of nicotine which will act on the body and satisfy some need. Experiments have revealed that nicotine has many actions on the body but only a very small proportion of these studies have used nicotine doses which are equivalent to smoking doses. The most consistent effect with smoking doses of nicotine is stimulation of a subset of the cholinergic neurones (ie the "nicotinic" pathways), including the autonomic nervous system and the ascending cholinergic pathways to the cortex and limbic system. The reason for this specificity of action is the similarity of the nicotine and acetylcholine molecules.

The outcome of these actions is an increase in blood levels of catecholamines and glucocorticoids and greater amounts of cortical desynchronization. All these changes are within the normal limits of the average person. Smokers believe that cigarettes alleviate mental and muscular fatigue to some extent and these effects can be attributed,

1002973504

in part, to the mobilization of energy reserves by the catecholamines and glucocorticoids. Smokers also claim that smoking helps them think and concentrate. Experimental studies with smokers have supported this claim and shown that nicotine can produce absolute enhancements in performance as well as preventing the performance decrements usually found during sustained performance. Enhanced performance of the same magnitude was found when nicotine tablets were given to non-smokers. A third important effect of nicotine is its sedative action which has been supported by questionnaire and experimental studies of smoking.

Measures of smoking behaviour during performance and while subjects are under stress show that smokers vary their nicotine intake according to the situation. In this way they obtain the required nicotine dose for stimulation or sedation depending on the situation. The rapid absorption and rapid metabolism make this substance suitable for hour-by-hour self-medication because of the personal control that can be exercised. In this respect nicotine is superior to other compounds for medication.

Nicotine taken in smoking doses seems to be relatively safe for healthy adults to use. On the evidence available at the moment it acts specifically on only a subset of the acetylcholine pathways in the body producing few side effects and none of these interfere with the normal functioning of body and mind. Even after a lifetime of use, the chronic toxicity of nicotine appears to be low. Thus nicotine stands in marked contrast to the deleterious short term and long term consequences of the socially acceptable substance, ethyl alcohol.

A number of important implications follow from these facts about nicotine. If smokers derive beneficial effects from nicotine and cigarettes are the most effective method of administering nicotine then cigarettes should be designed to deliver nicotine with minimum risk from smoke-related diseases. In my view the current trend of continuing to reduce nicotine as well as tar and carbon monoxide is not having the expected health benefits because smokers are compensating by puffing harder and inhaling more smoke. It has been argued that because compensation can only be partial with low delivery brands, intake of tar and carbon monoxide is still less than when high delivery brands were smoked and so

1002973505

these products have less risk (Rawbone, 1979). This argument would be true if cigarette consumption did not increase. However a recent paper (Wald et al, 1981) reported that over the 25 year period 1949-1974 sales-weighted average nicotine monotonically decreased. Tobacco industry figures confirm that sales-weighted nicotine monotonically decreased until 1975 from 1965, when its data were first available (RSL, 1981). In 1949, sales-weighted average nicotine was 74% higher than in 1974, representing a nicotine difference of 3.0% per annum. Over these 25 years, cigarette consumption for male smokers (RSL, 1981) increased by 50%, an average annual change of 2.0%, reflecting two-thirds compensation by consumption alone. The increase in consumption for women was even greater, as social influences contributed - it became more fashionable for females to smoke over this period. Since the mid-'70s, consumption has been affected by economic factors such as the recession and stringent tobacco taxation which make strong conclusions difficult. Nevertheless, it is intriguing that the recent downturn in consumption has coincided with a slight increase in average nicotine yield (Wald et al, 1981).

In conventional cigarette design, tar and nicotine tend to co-vary, ie low tar also entails low nicotine. Most popular cigarettes have a nicotine yield, as measured by a smoking machine, of at least 1.3 mg per cigarette, the best-selling brand having a nicotine yield of 1.6 mg per cigarette (DESS, 1981). Low tar cigarettes, however, have an average nicotine yield of only 0.7 mg per cigarette (about half popular requirement). Perhaps it is no coincidence that these low tar - low nicotine cigarettes have now, for a number of years, hovered around 15% market share - which is the same as the estimated proportion of "social smokers" (McKennell and Thomas, 1967), ie that minority group who, according to motivational researchers, smoke cigarettes for non-nicotine reasons (McKennell, 1973). For the majority of smokers, however, such low strength cigarettes are not satisfying: compensatory mechanisms became inadequate, as the effort necessary to generate required levels of nicotine is too great. A more effective approach for minimising risk and maximising benefit would be a product with medium nicotine delivery but a reduction of most other smoke components. For this concept to be acceptable, it is obviously crucial that such a cigarette also conveys sufficient flavour appeal. The Independent Scientific Committee already recognises the importance of flavour as a prerequisite for smoker satisfaction (Second Report, 1978). It is therefore essential that the product would not need to be smoked

1002973506

more intensively, or require more smoke to be inhaled, in order to satisfy taste, or to deliver the optimal amount of nicotine to the smoker. However, optimal levels of nicotine are different for different sorts of smokers. It seems to depend on such determinants as personality, sex, and average daily consumption. Thus specific types of products could be required to deliver the optimal nicotine levels for differing smoker groups.

The tobacco industry has methods for modifying smoke delivery in order to partially dissociate nicotine from tar. Some of the more drastic smoke reduction procedures change the chemical nature of the smoke (Guerin, 1980) and the toxicological implication of these shifts is unknown. Russell (1979) has briefly reported some tests of reduced tar, medium nicotine cigarettes but his comments imply that they were less acceptable than conventional products. Thus the manipulations of smoke delivery, that have been attempted so far, are very unsatisfactory, not only because they may leave harmful smoke compounds but because they remove important flavours. Clearly, future progress must be in the direction of reduction of specific smoke constituents to reduce risk but maintain flavour.

Unfortunately, we have only a limited amount of toxicological information on a few of the 4000 identified compounds in tobacco and tobacco smoke on which to base a selective reduction strategy. It is said that tobacco smoke is a relatively mild carcinogen (Tso, 1980) which means either that the hazardous compound or compounds are only weak carcinogens or the toxic compound is present in very small quantities. In the latter case the task of identification of the constituents to be reduced will be formidable.

Problems may also arise with the identification of key flavours because taste sensitivity is not uniform across the flavour spectrum. This non-uniformity means that some smoke constituents which are present in large amounts may contribute very little to smoke flavour while a trace component may be essential for a balanced sensory impact. Conceivably chemicals that are essential flavour components could also be hazardous (Second Report, 1978). In this case, non-toxic, flavour additives will have to be substituted for the desired flavour and to

1002973507

fortify the other flavours in order to preserve the characteristic full flavour impact for the smoker.

It is clear that the way to a less hazardous cigarette is not an easy one. However, the development of a medium nicotine cigarette, possibly with reduction of some smoke components, suitably enhanced with flavour, could well represent an important milestone along this path. The end of the road could not only be a safer cigarette but also a more satisfying one. Nicotine has much to commend it.

1002973508

23.

REFERENCES

ADAMS P I : Changes in personal smoking habits brought about by changes in cigarette smoke yield.

Proc 6th Int Tobacco Sci Cong, Tokyo: 102-108, 1976.

ADAMS P I : The influence of cigarette smoke yields on smoking habits.

In Smoking Behaviour, ed by R E Thornton, pp 349-360,
Churchill-Livingstone, Edinburgh, 1978.

ANDERSSON K : Effects of cigarette smoking on learning and retention.

Psychopharmacologia 41: 1-5, 1975a.

ANDERSSON K : Cigarette smoking, arousal and performance in a complex memory task.

Rep Dept Psychol Univer Stockholm, No.454, 1975b.

ANDERSSON K & HOCKEY, G R J : Effects of cigarette smoking on incidental memory.

Psychopharmacologia 52: 223-226, 1977.

ANDERSSON K & POST B : Effects of cigarette smoking on verbal rote learning and physiological arousal

Scand J Psychol 15: 263-267, 1974.

ARMITAGE A K : Some recent observations relating to the absorption of nicotine from tobacco smoke.

In Smoking Behaviour, ed by W L Dunn, pp 83-91, Winston (J Wiley), Washington DC, 1973.

ARMITAGE A K, DOLLERY C T, GEORGE C F, HOUSEMAN T H,

LEWIS P J and TURNER D M : Absorption and metabolism of nicotine by man during cigarette smoking.

Brit J Clin Pharmacol 1 : 180P-181P, 1974.

ARMITAGE A K, HALL G H and MORRISON C F : Pharmacological basis for the tobacco smoking habit.

Nature 217: 331-334, 1968.

1002973509

ARNITAGE A K, HALL G H and SELLERS C M : Effects of nicotine on electrocortical activity and acetylcholine release from the cat cerebral cortex.

Brit J Pharmacol 35: 152-150, 1969.

ARNITAGE A K and TURNER D M : Absorption of nicotine in cigarette and cigar smoke through the oral mucosa

Nature 226: 1231-1232, 1970.

ARTHO A J and GROB K : Nicotinabsorption aus dem Cigarettenrauch.

Z Präventivmed 9 : 14-25, 1964.

ASHTON H, MARSH V R, MILLMAN J E, RAWLINS M D, TELFORD R, THOMPSON J W :

The use of event-related slow potentials of the brain as a means to analyse the effects of cigarette smoking and nicotine in humans.

In Smoking Behaviour, ed by R E Thornton, pp 54-62,

Churchill-Livingstone, Edinburgh, 1978.

ASHTON H, MILLMAN J E, TELFORD R and THOMPSON J W : Stimulant and

depressant effects of cigarettes smoking on brain activity in man.

British Journal of Pharmacology 48: 715-717, 1973.

ASHTON H, MILLMAN J E, TELFORD R and THOMPSON J W : The effect of

caffeine, nitrazepam and cigarette smoking on the contingent

negative variation in man.

EEG Clin Neurophysiol 37: 59-71, 1974.

ASHTON H, MILLMAN J E, TELFORD R and THOMPSON J W : A comparison of

some physiological and psychological effects of propranolol and diazepam in normal subjects.

British Journal of Clinical Pharmacology 3: 551-559, 1976.

ASHTON H, STEPNEY R, and THOMPSON J W : Smoking behaviour and nicotine intake in smokers presented with a 'two-thirds' cigarette.

In Smoking Behaviour ed by R E Thornton, pp 315-329,

Churchill-Livingstone, Edinburgh, 1978.

1002973510

ASHTON H, STEPNEY R and THOMPSON J W : Self titration by cigarette holders.
Brit Med J 2 : 357-360, 1979.

ASETON H and TELFORD R : Blood carboxhaemoglobin levels in smokers.
Brit Med J 4 : 740, 1973.

ASHTON H and WATSON D W : Puffing frequency and nicotine intake in
cigarette smokers.
Brit Med J 3 : 679-681, 1970.

ÅSTRAND P O and RODAHL K : Textbook of Work Physiology
McGraw-Hill, New York, 1970.

BALTER M B : Drug abuse: a conceptual analysis and overview of the
current situation.
In Drug Use, ed by E Josephson and E E Carroll; pp 3-22,
Hemisphere Press (J Wiley), Washington DC, 1974.

BECKETT A H : Effects of drug-drug and drug-food interactions on
drug levels and performance in man.
In Chemical Influences on Behaviour, ed by R Porter and J Birch,
pp 89-108, Churchill, Edinburgh, 1970.

BECKETT A H and TRIGGS E J : Buccal absorption of basic drugs and its
application as an in vivo model of passive drug transfer through
lipid membranes.
J Pharm Pharmacol 19 : Suppl: 315-415, 1967.

BIRNIE C D and COMER A K : The effect of cigarette smoking on the
contingent negative variation (CNV) and eye movement.
In Smoking Behaviour, ed by R E Thornton, pp 69-75,
Churchill-Livingstone, Edinburgh, 1978.

BREIMER D D : Clinical pharmacokinetic and biopharmaceutical aspects
of hypnotic drug therapy.
In Sleep Research, ed by R G Priest, A Pletscher and J Ward,
pp 63-81, M.T.P. Press, Lancaster, UK, 1979.

1002973511

- BRODIE B B, MAICKEL R P and JONDORF W R : Termination of drug action by enzymatic inactivation.
Fed Proc 17: 1163-1174, 1958.
- CALIFANO J A : Remarks to the Fourth World Congress on Smoking and Health.
In The Smoking Epidemic, ed by L M Ramstrom, pp 118-122, Almquist and Wiksell, Stockholm, 1980.
- CARRUTHERS M : Worrying about anxiety.
Scot Med J 20: 289-290, 1975.
- CASTEDEN C M and COLE P V : Inhalation of tobacco smoke by pipe and cigar smokers.
Lancet 2 (7819): 21-22, 1973.
- CELESIA G G and JASPER E B : Acetylcholine released from the cerebral cortex in relation to state of activation.
Neurology 16: 1053-1063, 1966.
- CHERRY N and KIERNAN K : Personality scores and smoking behaviour - a longitudinal study.
Brit J Prevent Med 30: 123-131, 1976.
- CHERRY N and KIERNAN K : A longitudinal study of smoking and personality.
In Smoking Behaviour, ed by R E Thornton, pp 12-18, Churchill-Livingstone, Edinburgh, 1978.
- CHRISTENSEN E B and HANSEN O : Arbeitsfahigkeit and ehrnahrung.
Skand Arch Physiol 81: 160-178, 1939.
- COHEN A J and ROE F J C : Monograph on the Pharmacology and Toxicology of Nicotine.
Tobacco Advisory Council, London, 1981.
- COMER A K, BINNIE C D, BURNETT L, DARBY C E and THORNTON R E : The effect of cigarette smoking on the contingent negative variation (CNV) and eye movement.
(Abstract) EEG Clin Neurophysiol 39: 222, 1975.

1002973512

CRIEIGHTON D E and LEWIS P H : The effect of smoking pattern on smoke deliveries.

In Smoking Behaviour, ed by R E Thornton, pp 301-314,
Churchill-Livingstone, Edinburgh, 1978a.

CRIEIGHTON D E and LEWIS P H : The effect of different cigarettes on human smoking patterns.

In Smoking Behaviour, ed by R E Thornton, pp 289-300,
Churchill-Livingstone, Edinburgh, 1978b.

CRYER P E : Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system.

New Engl J Med 303: 435-444, 1980.

CRYER P E, HAMMOND M W, SANTIAGO J V, and SHAH S D : Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events.

New Engl J Med 295: 573-577, 1976.

CURTIS D R and RYALL R W : The excitation of Renshaw cells by cholinomimetics.

Exp Brain Res 2: 49-55, 1966.

DALE H H : The action of certain esters and ethers of choline, and their relation to muscarine.

J Pharm Exp Therap 6: 147-190, 1914.

DESS (Department of Health and Social Security)

Tar and Nicotine Table, 1981.

DOLL R and HILL A B : Mortality in relation to smoking: Ten years' observations of British doctors.

Brit Med J 1: 1399-1410 and 1460-1467, 1964.

DOMINO E F : Electroencephalographic and behavioural arousal effects of small doses of nicotine. A neuropsychopharmacological study.

Ann NY Acad Sci 142, 216-244, 1967.

1002973513

DOMINO E F : Neuropsychopharmacology of nicotine and tobacco smoking.

In Smoking Behaviour: Motives and Incentives by W L Dunn
pp 5-31, Winston, (J Wiley), Washington DC, 1973.

DUNNELL K and CARTWRIGHT A : Medicine Takers, Prescribers and Hoarders.
Routledge & Kegan Paul, London, 1972.

ECCLES J C, ECCLES R M, and FATT P : Pharmacological investigations on
a central synapse operated by acetylcholine.
J Physiol (Lond) 131: 154-169, 1956.

ECCLES J C and LIBET B: Origin and blockade of the synaptic
responses of curarized sympathetic ganglia.
J Physiol (Lond) 157: 484-503, 1956.

EDWARDS J : The psychophysiology of tobacco smoking.
I Electrocortical activity. Submitted for publication.

EDWARDS J, WESNES K, WARBURTON D M and GALE A : Event-Related
potentials and smoking. In preparation.

ENEROTE P, FUXE K, GUSTAFSSON J-Å, HOKFELT T, LOFSTROM A,
SKETT P and AGNATI L : The effect of nicotine on central catecholamine
neurones and gonadotrophin secretion II.
Med Biol 55: 153-156, 1977a.

ENEROTE P, FUXE K, GUSTAFSSON J-Å, HOKFELT T, LOFSTROM A,
SKETT P and AGNATI L : The effect of nicotine on central catecholamine
neurones and gonadotrophin secretion III.
Med Biol 55: 167-176, 1977b.

ESSMAN W B : Metabolic and behavioral consequences of nicotine.
In Drugs and Cerebral Function, ed by W L Smith, pp 46-84,
Charles C Thomas, Springfield US, 1981.

EYSENCK H J : Personality and cigarette smoking.
Life Sci 3 : 777-792, 1963.

1002973514

EYSENCK H J and EYSENCK S B G : Manual of the Eysenck Personality Inventory.
University of London Press, London, 1964.

FINNEGAN J K, LARSON P S and HAAG H B : The role of nicotine in the
cigarette habit.
Science 102: 94-96, 1945.

FISHER V E : An experimental study of the effects of tobacco smoking on
certain psychophysiological functions.
Comp Psychol Monog 4 No.19 whole issue, 1927.

FORBES W F, ROBINSON J C, HANLEY J A and COLBURN H N : Studies of the nicotine
exposure of individuals: I Changes in mouth level exposure to nicotine on
switching to lower nicotine cigarettes.
Int J Addic 11: 933-950, 1976.

FRANKENHAUSER M, MYRSTEN A L, POST B and JOHANSSON G : Behavioural
and physiological effects of cigarette smoking in a monotonous
situation.
Psychopharmacologia 22: 1-7, 1981.

FREEDMAN S, and FLETCHER C M : Changes of smoking habits and cough
in men smoking cigarettes with 30% NSM tobacco substitute.
Brit Med J 3: 1427-1430, 1976.

FRITH C D : Smoking behaviour and its relation to the smoker's
immediate experience.
Brit J Soc Clin Psychol 10: 73-78, 1981.

FURCHGOTT R F : Receptor mechanisms.
Ann Rev Pharmacol 4: 21-50, 1964.

FUXE K, AGNATI L, ENEROTH P, GUSTAFSSON J-Å, HOKFELT J,
LOFSTROM A, SKETT B, and SKETT P : The effect of nicotine on
central catecholamine neurones and gonadotropin secretion I.
Med Biol 55: 148-157, 1977.

GILBERT R M : Caffeine as a drug of abuse.
In Research Advances in Alcohol and Drug Problems, Vol ed by
R J Gibbins, Y Israel, H Kalant, R E Popham, W Schmidt, R G Smart,
pp 49-176, Wiley, New York. 1976

1002973515

GOLDFARB T L and JARVIK J E : Accommodation to restricted tobacco smoke intake in cigarette smokers.

Int J Addict 7: 559-565, 1972.

GOLDFARB T L, JARVIK M E and GLICK S D : Cigarette nicotine content as a determinant of human smoking behaviour.

Psychopharmacologia 17: 89-93, 1980.

GRITZ E R, BAER-WEISS V and JARVIK M E : Titration of nicotine intake with full-length and half-length cigarettes.

Clin Pharmacol Therap 20: 552-556.

GUERIN, M R : Chemical composition of cigarette smoke.

In A Safe Cigarette? (Banbury Report 3), ed by G B Gori and F G Bock, pp 191-201, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1980.

GUILFORD J S : Factors Related to Successful Abstinence from Smoking.

Pittsburgh, American Institutes for Research, 1966.

GUILLERM R, MASUREL G, BROUSSELLE B, HYACINTHE R, SIMON A and HEE J :

Effets cliniques et fonctionnels respiratoires de la substitution d'une cigarette peu irritante a la cigarette habituelle dans une groupe de grands fumeurs.

Les bronches 24: 209-231, 1974.

HALPERIN M E, MCFARLAND R A, NIVEN J J and ROUGHTON F J W: The time course of the effects of carbon monoxide on visual thresholds.

J Physiol (Lond) 146: 583-593.

HAMMOND E C : Smoking in relation to the death rates of one million men and women.

In Epidemiological approaches to the Study of Cancer, ed by W. Haenszel, pp 127-204, National Cancer Institute Monograph, US Department of Health, Education and Welfare, Washington DC, 1966.

HARRIS L S : Cannabis: A review of progress.

In Psychopharmacology: A Generation of Progress, ed by M A Lipton, A DiNascio, and K F Killam, pp 1565-1574, Raven Press, New York, 1978.

HAUSER H, SCHWARTZ B, ROTH G and BICKFORD R : Electroencephalographic changes related to smoking.

EEG Clin Neurophysiol

1002973516

Int J Addict 7: 559-565, 1972.

GOLDFARB T L, JARVIK M E and GLICK S D : Cigarette nicotine content as a determinant of human smoking behaviour.
Psychopharmacologia 17: 89-93, 1980.

GRITZ E R, BAER-WEISS V and JARVIK M E : Titration of nicotine intake with full-length and half-length cigarettes.
Clin Pharmacol Therap 20: 552-556.

GUERIN, M R : Chemical composition of cigarette smoke.

In A Safe Cigarette?(Banbury Report 3), ed by G B Gori and F G Bock, pp 191-201, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1980.

GUILFORD J S : Factors Related to Successful Abstinence from Smoking.
Pittsburgh, American Institutes for Research, 1966.

GUILLERM R, MASUREL G, BROUSSELLE B, HYACINTHE R, SIMON A and HEE J : Effets cliniques et fonctionnels respiratoires de la substitution d'une cigarette peu irritante a la cigarette habituelle dans une groupe de grands fumeurs.
Les bronches 24: 209-231, 1974.

HALPERIN M H, MCFARLAND R A, NIVEN J J and ROUGHTON F J W: The time course of the effects of carbon monoxide on visual thresholds.
J Physiol (Lond) 146: 583-593.

HAMMOND E C : Smoking in relation to the death rates of one million men and women.

In Epidemiological approaches to the Study of Cancer, ed by W Haenszel, pp 127-204, National Cancer Institute Monograph, US Department of Health, Education and Welfare, Washington DC, 1966.

HARRIS L S : Cannabis: A review of progress.

In Psychopharmacology: A Generation of Progress, ed by M A Lipton, A DiMascio, and K F Killam, pp 1565-1574, Raven Press, New York, 1978.

HAUSER H, SCHWARTZ B, ROTH G and BICKFORD R : Electroencephalographic changes related to smoking.
EEG. Clin. Neurophysiol., 10: 576
(Abstract), 1958.

1002973517

HEINSTRAN W, BANCROFT N R and DEKOCK A R: Effects of smoking upon sustained performance in a simulated driving task.

Ann NY Acad Sci 142: 295-307, 1967.

HOUSTON J P, SCHNEIDER N G & JARVIK M E: Effects of smoking on free-recall and organization in short and long-term memory.

Am J Psychiatry 135: 220-222, 1978.

HOUTEAKKER H S and TAYLOR L D: Consumer Demand in the United States, 1929 - 1970. Harvard University Press, Cambridge, Mass, 1966.

HERDING P D: Metabolism of brain acetylcholine and its modification by drugs.

Drug Metab. Rev 3: 89-129, 1974.

HULL C: The influence of tobacco smoking on mental and motor efficiency. Psychol Monog 33: No.150, 1924.

HUNT W A, BESPALC D A: An evaluation of current methods of modifying smoking behaviour.

J Clin Psychol 30: 431-438, 1974.

ISRAEL Y and MARDONES J: Biological Basis of Alcoholism Wiley, New York, 1971.

JARVIK M E, GLICK S D, NAKAMURA R K: Inhibition of cigarette smoking by orally administered nicotine.

Clin Pharmacol Therap 11: 574-576, 1980.

JARVIK M E, POPEK P, SCHNEIDER N G, BAER-WEISS V and GRITZ E R: Can cigarette size and nicotine content influence smoking and puffing rates.

Psychopharmacology 58: 303-306, 1978.

KATZ B and THESLEFF S: A study of desensitization produced by acetylcholine at the motor end plate.

J Physiol, London 138: 63-80, 1957.

1002973518

KAWAYURA H and DOMINO E F : Differential actions of m and n cholinergic agonists on the brainstem activating system.
Int J Neuropharm 8: 105-115, 1969.

KERSHBAUM A and BELLET S : Cigarette, cigar and pipe smoking: Some differences in biochemical effects.
Geriatrics 23: 126-134, 1968.

KERSHBAUM A, PAPPAJOHN D J, BELLET S, HIRABAYASHI M and SHAPIRO H: Effect of smoking and nicotine on adrenocortical secretion.
J Amer Med Assoc 203: 275-278, 1968.

MILOR L G and BRANDON S : Habituation and addiction to amphetamines.
Brit Med J 2: 40-43, 1962.

KISSIN B : Alcohol as it compares to other addictive substances.
In Drug Abuse, ed by W Kaup, pp 251-262
Charles C Thomas, Springfield, Ill, 1972.

KRAPP D E and DOMINO E F : Action of nicotine on the ascending reticular activating system.
Int J Neuropharm 1: 333-351, 1962.

KNOTT V J : Psychophysiological correlates of smokers and non-smokers: studies on cortical, autonomic and behavioural responsivity.
In Electrophysiological Effects of Nicotine, ed by A Remond and C Izard, pp 99-116, Elsevier - North Holland Biomedical Press, Amsterdam, 1979.

KORNETSKY C : Pharmacology: Drugs Affecting Behavior.
Wiley, New York, 1976.

KUMAR R, COOKE E C, LADER M E, and RUSSELL M A H : Is nicotine important in tobacco smoking?
Clin Pharm Therap 21: 520-529, 1977.

1002973519

LARSSON P S, FINNEGAN J, and HAAG H B : Observations on the effect of cigarette smoking on the fusion frequency of flicker.
J Clin Invest 29: 483-486, 1950.

LARSSON P S, HAAG H B and SILVETTE H : Tobacco: Experimental and Clinical Studies, Williams & Wilkins Co, Baltimore, 1961.

LATIES V G and MERIGAN W H : Behavioural effects of carbon monoxide on animals and man.
Ann Rev Pharmacol Toxicol 19: 357-392, 1979.

LEE P N : Has the mortality of male doctors improved with the reductions in their cigarette smoking?
Brit Med J 2: 1538-1540, 1979.

LEMBERGER L and RUBIN A : Physiological Disposition of Drugs of Abuse.
Spectrum (J Wiley), New York, 1976.

LICHTENSTEIGER W : Interaction of acetylcholine in neuroendocrine function.
In Biologique Cellulaire des Processus Neurosecretoires Hypothalamiques,
ed by J C Vincent and C Kornon, pp 179-191, Colloques Internationaux
du C.N.R.S., Paris, 1979.

LICHTENSTEIGER W, FELIX D, LIENHART R and HEFTI F : A quantitative correlation between single unit activity and fluorescence intensity of dopamine neurones in zona compacta of substantia nigra, as demonstrated under the influence of nicotine and physostigmine.
Brain Res 117: 85-103, 1976.

LICHTENSTEIGER W, RICHARDS J G and KOPP H G : Changes in the distribution of non-neuronal units in rat median eminence and in anterior pituitary hormone secretion after activation of tuberoinfundibular dopamine neurones by brain stimulation or nicotine.
Brain Res 157: 13-88, 1978.

LUCCHESI B R, SCHUSTER C R, and EMLEY G S : The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid.
Clin Pharm Therap 8: 789-796, 1967.

1002973520

MACMAHON B, YEN S, TRICHOPOULOS D, WARREN K and NARDI G : Coffee and Cancer of the Pancreas
New Eng J Med 304: 630-633, 1981.

MARKS J : The Benzodiazepines: Use, Overuse, Misuse, Abuse.
M.T.P. Press, Lancaster, UK, 1978.

MARKS V and KELLY J F : Absorption of caffeine from tea, coffee and Coca Cola.
Lancet 1: 827, 1973.

MARLATT A : A cognitive-behavioral model of the relapse process.
In Behavioural Analysis and Treatment of Substance Abuse, ed by J Krasnegor, pp 191-199, National Institute for Drug Abuse, Washington, DC, 1979.

MAUSNER J S : Cigarette smoking among patients with respiratory disease.
Ann Rev Respir Dis 102: 704-706.

McKENNELL A C : Smoking motivation factors.
Brit J Soc Clin Psychol 9: 8-22, 1970.

McKENNELL A C : A Comparison of Two Smoking Typologies
TRC Research Paper 12, 1973.

McKENNELL A C and THOMAS R K : Adults and Adolescents' Smoking Habits and Attitudes.
EMSO, 1967.

MEARES R, GRIMWADE J, BICKLEY M, and WOOD C : Smoking and neuroticism.
Lancet 2 : 770, 1971.

MURPHREE, E B : EEG effects in humans of nicotine, tobacco smoking, withdrawal from smoking and possible surrogates.
In Electrophysiological Effects of Nicotine, ed by A Rémond and C Ezard, pp 227-244, Elsevier - North Holland Biomedical Press, Amsterdam, 1979.

1002973521

MYRSTEN A-L, ANDERSSON K, FRANKENHAEUSER M and MARDH A : Immediate effects of cigarette smoking as related to different smoking habits. Rep Psychol Labs 378, Univ Stockholm, Stockholm, 1972.

MYRSTEN A-L, POST B, FRANKENHAEUSER M, JOHANSSON G : Changes in behavioural and physiological activation induced by cigarette smoking in habitual smokers. Psychopharmacologia 27: 305-312, 1972.

NESBITT P D : Smoking, physiological arousal and emotional response. Journal of Personality and Social Psychology 25: 137-144, 1973.

OLDENDORF W E : Distribution of drugs in the brain. In Psychopharmacology in the Practice of Medicine, ed by M E Jarvik, pp 167-175, Appleton-Century-Crofts, New York, 1977.

OLDENDORF W E, HYMAN S, BRAUN L, OLDENDORF S Z: Blood-brain barrier: penetration of morphine, codeine, heroine and methadone after carotid injection. Science, 176: 984-987, 1972.

OVIEDO Y VALDES G F DE: Historia general y natural de las Indias. Quoted in Robicack, 1978.

PANGBORN R M and TRABUE I M : Gustatory responses during periods of controlled and ad lib cigarette smoking. Percep Psychophys 1 : 139-144, 1973.

PATON W D M and PERRY W L M : The relationship between depolarization and block in the cat's superior cervical ganglion. J Physiol (London) 119: 43-57, 1953.

PAULING P : The conformation of molecules affecting cholinergic nervous systems. In Drugs and Cholinergic Mechanisms in the CNS, ed by E Heilbronn and A Winter, Research Institute of National Defence, Stockholm, 1980.

PEPEU G : Nicotina e acetilcolina cerebrale. Arch Ital Sci Farmacol, 15: 93-94, 1965.

1002973522

PROOSDIJ C : Smoking, its influence on the individual and its role in social medicine.

Elsevier, New York, 1960.

RAE G : Extraversion, neuroticism and cigarette smoking.

Brit J Soc Clin Psychol 14: 429-430, 1975.

RAWBONE R G : Nicotine, tobacco substitutes and smoking habits.

Brit Med J 2: 177, 1976.

RAWBONE R G : Self-titration by cigarette smokers.

Brit Med J 2: 731-732, 1979.

RAWBONE R G, MURPHY K, TATE M E and KANE S J : The analysis of smoking parameters, inhalation and absorption of tobacco smoke in studies of human smoking behaviour.

In Smoking Behaviour, ed by R E Thornton, pp 171-194,
Churchill-Livingstone, Edinburgh, 1978.

ROYAL COLLEGE OF PHYSICIANS: Smoking and Health

Pitman, London, 1962.

RSL (Research Services Limited): TAC Statistics of Smoking.

(J.2770/AS), 1981.

RUSSELL M A H : Tobacco smoking and nicotine dependence.

In Research Advances in Alcohol and Drug Problems, Vol 3,
ed by R J Gibbins, Y Israel, B Kalant, R E Popham, W Schmidt,
and R G Smart, pp 1-48, Wiley, New York, 1976.

RUSSELL M A H : Low tar - medium nicotine cigarettes: a new approach to safer smoking.

Brit Med J 1: 1430-1433, 1976.

RUSSELL M A H, JARVIS M J and FEYERABEND C: A new age for snuff?

Lancet 1: 474-475.

RUSSELL M A H : Prevention of smoke-related disease.

In Prospects for Prevention, ed A T Proudfoot,
pp 55-74, Royal College of Physicians, Edinburgh, 1979.

1002973523

RUSSELL M A H, SUTTON S R, FEYERABEND C and SALOOJEE Y : Smokers response to shortened cigarettes: Dose reduction without dilution of tobacco smoke.

Clin Pharmacol Therap 27: 210-218, 1980.

RUSSELL M A H, PETO J and PATEL U A : The classification of smoking by factorial structure of motives.

J Roy Stat Soc A 137: 313-333, 1974.

RUSSELL M A H, SUTTON S R, FEYERABEND C and COLE P V : Addiction Research Unit nicotine titration studies.

In Smoking Behaviour, ed R E Thornton, pp 336-348, Churchill-Livingstone, Edinburgh, 1978.

RUSSELL M A H and WESNES K

Unpublished data.

RUSSELL M A H, WILSON C, FEYERABEND C and COLE P V : Effect of nicotine chewing gum as substitute for smoking.

Brit Med J 2: 391-393.

RUSSELL M A H, WILSON C, PATEL U A, COLE P V and FEYERABEND C : Comparison of effect on tobacco consumption and carbon monoxide absorption of changing to high and low nicotine cigarettes.

Brit Med J 4: 512-516, 1973.

RUSSELL M A H, WILSON C, PATEL U A, FEYERABEND C and COLE P V : Plasma nicotine levels after smoking cigarettes with high, medium and low nicotine yields.

Brit Med J 2: 414-416, 1975.

SCHACHTER S : Nicotine regulation in heavy and light smokers.

J Exp Psychol 106: 5-12, 1977.

SCHACHTER S : Pharmacological and psychological determinants of smoking.

Ann Int Med 88: 104-114, 1978a.

1002973524

SCHACHTER S : Pharmacological and psychological determinants of smoking.
In Smoking Behaviour ed by R E Thornton, pp 208-228,
Churchill-Livingstone, Edinburgh, 1978b.

SCHACHTER S, KOZLOWSKI L, and SILVERSTEIN B : Effects of urinary pH
on cigarette smoking.
J Exp Psychol 106: 13-19, 1977.

SCHACHTER M D, and RAND M J : Effect of acute deprivation of smoking on
aggression and hostility.
Psychopharmacologia 35: 19-28, 1974.

SCHMITTERLOW C G, HANSSON E, ANDERSSON G, APPELGREN L E and HOFFMAN P C :
Distribution of nicotine in the central nervous system.
Ann NY Acad Sci, 142: 2-14, 1967.

SCHULTES T W : The future of plants as sources of new biodynamic
compounds.
In Plants in the Development of Modern Medicine, ed by T Swain,
pp 103-124, Harvard University Press, Cambridge, Mass, 1972.

SECOND REPORT OF THE INDEPENDENT SCIENTIFIC COMMITTEE ON SMOKING AND
HEALTH: Developments in Tobacco Products and the Possibility
of "Lower-Risk" Cigarettes.
HMSO (ISBN: 0-11-320717-4) p4, 1978.

SHIFFMAN S M : The tobacco withdrawal syndrome.
In Cigarette Smoking as a Dependence Process, ed by N A
National Institute for Drug Abuse, Washington DC, 1979a.

SHIFFMAN S M : Analysis of relapse episodes following smoking cessation.
Paper presented at the 4th World Congress on Smoking and Health.

SHIFFMAN S M and JARVIK M E : Smoking withdrawal symptoms in two weeks
of abstinence.
Psychopharmacology, 50: 35-39, 1976.

1002973525

SNUTE C C D and LEWIS P R : The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections.
Brain, 90: 497-520, 1967.

STALEANDSKE T : Effects of increased liver metabolism of nicotine on its uptake, elimination and toxicity in mice.
Acta Physiol Scand 80: 222-234, 1970.

STOLERMAN I P, GOLDFARB T, FINK R, and JARVIC M E : Influencing cigarette smoking with nicotine antagonists.
Psychopharmacologia 28: 247-259, 1973.

SUTTON S R, RUSSELL M A H, FEYERABEND C and SALOOJEE Y : Smokers response to dilution of smoke by ventilated cigarette holders.
In Smoking Behaviour, ed by R E Thornton, pp 330-335,
Churchill-Livingstone, Edinburgh, 1978.

TARRIERE C and HARTEMANN F : Investigation into the effects of tobacco smoke on a visual vigilance task.
Ergonomics, Proc 2nd Int Eng Assoc Cong, 525, 530, 1964.

TEMPLE D J : The absorption of nicotine from tobacco snuff through the nasal mucosa.
Arch Pharm 509: 984-987, 1976.

THOMAS C B _ The relationship of smoking and habits of nervous tension.
In Smoking Behaviour, ed W L Dunn, pp 157-170, Winston (J Wiley), New York, 1973.

TODD G F : Statistics of Smoking in the United Kingdom (5th Edition).
Tobacco Research Council, London, 1969.

TODD G F : Statistics of Smoking in the United Kingdom (6th Edition).
Tobacco Research Council, London, 1972.

TRAVELL J : Absorption of nicotine from various sites.
Ann NY Acad Sci 90: 13-30, 1960.

1002973526

TSO T C : Modification through agricultural techniques for developing safer tobacco.

In A Safe Cigarette? (Banbury Report 3), ed by G B Gori and F G Bock, pp 181-189, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1980.

TURNER J A M, SILLETT R W and BALL K P : Some effects of changing to low-tar and low-nicotine cigarettes.
Lancet 2: 737-739, 1974.

US DEPARTMENT OF HEALTH AND HUMAN SERVICES: The Health Consequences of Smoking - Cancer.
Report of the Surgeon General, 1981.

US PUBLIC HEALTH SERVICE: The Health Consequences of Smoking.
A report to the Surgeon General: 1964 US Department of Health, Education and Welfare. Washington DC, 1964.

US PUBLIC HEALTH SERVICE : Smoking and Health.
A report to the Surgeon General: 1979. US Department of Health, Education, and Welfare, Washington DC, 1979.

WAINGROW S and HORN D : Relationship of number of cigarettes smoked to "tar" rating.
Nat Cancer Inst Mong 28: 29-33, 1968.

WALD N, DOLL R and COPELAND G : Trends in tar, nicotine and carbon monoxide yields of UK cigarettes manufactured since 1934.
Brit Med J 282: 763-765, 1981.

WALLGREN H and BARRY H : Actions of Alcohol.
Elsevier, Amsterdam, 1971.

WARBURTON D M : Brain, Behaviour and Drugs.
Wiley, London, 1975.

WARBURTON D M : Stimulus selection and behavioural inhibition.
In Handbook of Psychopharmacology, Vol 8, ed L L Iversen, S D Iversen, and S H Snyder, pp 131-147, Plenum Press, New York, 1977.

1002973527

TSO T C : Modification through agricultural techniques for developing
safer tobacco.

In A Safe Cigarette? (Banbury Report 3), ed by G B Gori and F G Bock,
pp 161-189, Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY, 1980.

TURNER J A M, SILLETT R W and BALL K P : Some effects of changing to
low-tar and low-nicotine cigarettes.
Lancet 2: 737-739, 1974.

US DEPARTMENT OF HEALTH AND HUMAN SERVICES: The Health Consequences
of Smoking - Cancer.
Report of the Surgeon General, 1981.

US PUBLIC HEALTH SERVICE: The Health Consequences of Smoking.
A report to the Surgeon General: 1964 US Department of Health,
Education and Welfare. Washington DC, 1964.

US PUBLIC HEALTH SERVICE : Smoking and Health.
A report to the Surgeon General: 1979. US Department of Health,
Education, and Welfare, Washington DC, 1979.

WAINGROW S and HORN D : Relationship of number of cigarettes smoked
to "tar" rating.
Nat Cancer Inst Mong 28: 29-33, 1968.

WALD N, DOLL R and COPELAND G : Trends in tar, nicotine and carbon monoxide
yields of UK cigarettes manufactured since 1934.
Brit Med J 282: 763-765, 1981.

WALLGREN H and BARRY H : Actions of Alcohol.
Elsevier, Amsterdam, 1971.

WARBURTON D M : Brain, Behaviour and Drugs.
Wiley, London, 1975.

WARBURTON D M : Stimulus selection and behavioural inhibition.
In Handbook of Psychopharmacology, Vol 8, ed L L Iversen, S D Iversen,
and S H Snyder, pp 131-147, Plenum Press, New York, 1977.

1002973528

WARBURTON D M : Physiological aspect of anxiety and schizophrenia.
In Stress and Cognition, ed by V Hamilton and D M Warburton
pp 431-468, Wiley, London, 1979.

WARBURTON D M : Neurochemical bases of behaviour.
Brit Med Bull 37: 121-125, 1981.

WARBURTON D M and WESNES K : Individual differences in smoking
and attentional performance.
In Smoking Behaviour, ed by R E Thornton, pp 19-43,
Churchill-Livingstone, Edinburgh, 1978.

WARBURTON D M and WESNES K : The role of electrocortical arousal in
the smoking habit.
In Electrophysiological Effects of Nicotine, ed by A Remond and
C Izard, pp 183-200, Elsevier - North Holland Biomedical Press, 1979.

WARBURTON D M, WESNES K and REVELL A : Personality factors in self-
medication by smoking.
In Response Variability to Psychotropic Drugs, ed by W Janke,
in press, Pergamon Press, London, 1982.

WARBURTON D M, WESNES K and SHERGOLD K : Facilitation of learning
and state dependency with nicotine.
Proc 13th C.I.N.P. Cong, in press.

WARWICK K M and EYSENCK H J : The effects of smoking on the CFF
threshold.
Life Sci 4: 219-225, 1963.

WATERS W E : Smoking and neuroticism.
Brit J Prevent Soc Med 25: 162-164, 1971.

WESNES K, PITKETHLY G M and WARBURTON D M : Oral Nicotine preload
and smoking behaviour, in preparation.

WESNES K and WARBURTON D M : The effects of cigarettes smoking and
nicotine tablets upon human attention.
In Smoking Behaviour, ed R E Thornton, pp 131-147,
Churchill-Livingstone, Edinburgh, 1978.

1002973529

WESNES K and WARBURTON D M : Stress, drugs and performance, ed by G R J Hockey
In Stress and Fatigue in Human Performance, in press,
Wiley, London, 1983.

WESTFALL T C, FLEMING R M, FUDGER M F and CLARK W G : Effect of nicotine
and related substances upon amine levels in the brain.
Ann NY Acad Sci 142: 83-100, 1967.

WESTFALL T C : Effect of nicotine and other drugs on the release of
³H-norepinephrine and ³H-dopamine from rat brain slices.
Neuropharm 13: 693-800, 1974.

WINTERNITZ W W and QUILLEN D : Acute hormonal response to cigarette smoking.
J Clin Pharm 17: 389-397, 1977.

May 1982

PROFESSOR D M WARBURTON

1002973530